-
Notifications
You must be signed in to change notification settings - Fork 0
/
Copy pathneo4j_graph_visualization.html
222 lines (166 loc) · 142 KB
/
neo4j_graph_visualization.html
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
<html>
<head>
<meta charset="utf-8">
<script src="lib/bindings/utils.js"></script>
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/dist/vis-network.min.css" integrity="sha512-WgxfT5LWjfszlPHXRmBWHkV2eceiWTOBvrKCNbdgDYTHrT2AeLCGbF4sZlZw3UMN3WtL0tGUoIAKsu8mllg/XA==" crossorigin="anonymous" referrerpolicy="no-referrer" />
<script src="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/vis-network.min.js" integrity="sha512-LnvoEWDFrqGHlHmDD2101OrLcbsfkrzoSpvtSQtxK3RMnRV0eOkhhBN2dXHKRrUU8p2DGRTk35n4O8nWSVe1mQ==" crossorigin="anonymous" referrerpolicy="no-referrer"></script>
<center>
<h1></h1>
</center>
<!-- <link rel="stylesheet" href="../node_modules/vis/dist/vis.min.css" type="text/css" />
<script type="text/javascript" src="../node_modules/vis/dist/vis.js"> </script>-->
<link
href="https://cdn.jsdelivr.net/npm/[email protected]/dist/css/bootstrap.min.css"
rel="stylesheet"
integrity="sha384-eOJMYsd53ii+scO/bJGFsiCZc+5NDVN2yr8+0RDqr0Ql0h+rP48ckxlpbzKgwra6"
crossorigin="anonymous"
/>
<script
src="https://cdn.jsdelivr.net/npm/[email protected]/dist/js/bootstrap.bundle.min.js"
integrity="sha384-JEW9xMcG8R+pH31jmWH6WWP0WintQrMb4s7ZOdauHnUtxwoG2vI5DkLtS3qm9Ekf"
crossorigin="anonymous"
></script>
<center>
<h1></h1>
</center>
<style type="text/css">
#mynetwork {
width: 100%;
height: 750px;
background-color: #ffffff;
border: 1px solid lightgray;
position: relative;
float: left;
}
#loadingBar {
position:absolute;
top:0px;
left:0px;
width: 100%;
height: 750px;
background-color:rgba(200,200,200,0.8);
-webkit-transition: all 0.5s ease;
-moz-transition: all 0.5s ease;
-ms-transition: all 0.5s ease;
-o-transition: all 0.5s ease;
transition: all 0.5s ease;
opacity:1;
}
#bar {
position:absolute;
top:0px;
left:0px;
width:20px;
height:20px;
margin:auto auto auto auto;
border-radius:11px;
border:2px solid rgba(30,30,30,0.05);
background: rgb(0, 173, 246); /* Old browsers */
box-shadow: 2px 0px 4px rgba(0,0,0,0.4);
}
#border {
position:absolute;
top:10px;
left:10px;
width:500px;
height:23px;
margin:auto auto auto auto;
box-shadow: 0px 0px 4px rgba(0,0,0,0.2);
border-radius:10px;
}
#text {
position:absolute;
top:8px;
left:530px;
width:30px;
height:50px;
margin:auto auto auto auto;
font-size:22px;
color: #000000;
}
div.outerBorder {
position:relative;
top:400px;
width:600px;
height:44px;
margin:auto auto auto auto;
border:8px solid rgba(0,0,0,0.1);
background: rgb(252,252,252); /* Old browsers */
background: -moz-linear-gradient(top, rgba(252,252,252,1) 0%, rgba(237,237,237,1) 100%); /* FF3.6+ */
background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,rgba(252,252,252,1)), color-stop(100%,rgba(237,237,237,1))); /* Chrome,Safari4+ */
background: -webkit-linear-gradient(top, rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Chrome10+,Safari5.1+ */
background: -o-linear-gradient(top, rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Opera 11.10+ */
background: -ms-linear-gradient(top, rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* IE10+ */
background: linear-gradient(to bottom, rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* W3C */
filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#fcfcfc', endColorstr='#ededed',GradientType=0 ); /* IE6-9 */
border-radius:72px;
box-shadow: 0px 0px 10px rgba(0,0,0,0.2);
}
</style>
</head>
<body>
<div class="card" style="width: 100%">
<div id="mynetwork" class="card-body"></div>
</div>
<div id="loadingBar">
<div class="outerBorder">
<div id="text">0%</div>
<div id="border">
<div id="bar"></div>
</div>
</div>
</div>
<script type="text/javascript">
// initialize global variables.
var edges;
var nodes;
var allNodes;
var allEdges;
var nodeColors;
var originalNodes;
var network;
var container;
var options, data;
var filter = {
item : '',
property : '',
value : []
};
// This method is responsible for drawing the graph, returns the drawn network
function drawGraph() {
var container = document.getElementById('mynetwork');
// parsing and collecting nodes and edges from the python
nodes = new vis.DataSet([{"color": "#97c2fc", "id": "NCT03821493", "label": "NCT03821493", "shape": "dot", "title": "SubjectNode: NCT03821493"}, {"color": "#97c2fc", "id": "Advanced Solid Malignancies", "label": "Advanced Solid Malignancies", "shape": "dot", "title": "ObjectNode: Advanced Solid Malignancies"}, {"color": "#97c2fc", "id": "Hepatitis B e Antigen Seroconversion", "label": "Hepatitis B e Antigen Seroconversion", "shape": "dot", "title": "ObjectNode: Hepatitis B e Antigen Seroconversion"}, {"color": "#97c2fc", "id": "hypersensitivity itraconazole", "label": "hypersensitivity itraconazole", "shape": "dot", "title": "ObjectNode: hypersensitivity itraconazole"}, {"color": "#97c2fc", "id": "diagnosed chronic heart failure", "label": "diagnosed chronic heart failure", "shape": "dot", "title": "ObjectNode: diagnosed chronic heart failure"}, {"color": "#97c2fc", "id": "Body weight \u2265 45 kg", "label": "Body weight \u2265 45 kg", "shape": "dot", "title": "ObjectNode: Body weight \u2265 45 kg"}, {"color": "#97c2fc", "id": "BMI 18 to 32 kg/m2", "label": "BMI 18 to 32 kg/m2", "shape": "dot", "title": "ObjectNode: BMI 18 to 32 kg/m2"}, {"color": "#97c2fc", "id": "Maximum Observed Plasma Analyte Concentration", "label": "Maximum Observed Plasma Analyte Concentration", "shape": "dot", "title": "ObjectNode: Maximum Observed Plasma Analyte Concentration"}, {"color": "#97c2fc", "id": "AUCinf of PF-06835919", "label": "AUCinf of PF-06835919", "shape": "dot", "title": "ObjectNode: AUCinf of PF-06835919"}, {"color": "#97c2fc", "id": "Isavuconazole", "label": "Isavuconazole", "shape": "dot", "title": "ObjectNode: Isavuconazole"}, {"color": "#97c2fc", "id": "Healthy Fed Participants", "label": "Healthy Fed Participants", "shape": "dot", "title": "ObjectNode: Healthy Fed Participants"}, {"color": "#97c2fc", "id": "NCT04544293", "label": "NCT04544293", "shape": "dot", "title": "SubjectNode: NCT04544293"}, {"color": "#97c2fc", "id": "Baseline to Week 49", "label": "Baseline to Week 49", "shape": "dot", "title": "ObjectNode: Baseline to Week 49"}, {"color": "#97c2fc", "id": "Baseline to 28 days", "label": "Baseline to 28 days", "shape": "dot", "title": "ObjectNode: Baseline to 28 days"}, {"color": "#97c2fc", "id": "SGRQ Activity component score", "label": "SGRQ Activity component score", "shape": "dot", "title": "ObjectNode: SGRQ Activity component score"}, {"color": "#97c2fc", "id": "St. George\u0027s Hospital Respiratory Questionnaire", "label": "St. George\u0027s Hospital Respiratory Questionnaire", "shape": "dot", "title": "ObjectNode: St. George\u0027s Hospital Respiratory Questionnaire"}, {"color": "#97c2fc", "id": "Change from baseline in Peak FEV1 response", "label": "Change from baseline in Peak FEV1 response", "shape": "dot", "title": "ObjectNode: Change from baseline in Peak FEV1 response"}, {"color": "#97c2fc", "id": "Inhaled Molgramostim Nebulizer Solution", "label": "Inhaled Molgramostim Nebulizer Solution", "shape": "dot", "title": "ObjectNode: Inhaled Molgramostim Nebulizer Solution"}, {"color": "#97c2fc", "id": "Idiopathic Pulmonary Fibrosis", "label": "Idiopathic Pulmonary Fibrosis", "shape": "dot", "title": "ObjectNode: Idiopathic Pulmonary Fibrosis"}, {"color": "#97c2fc", "id": "NCT03181893", "label": "NCT03181893", "shape": "dot", "title": "SubjectNode: NCT03181893"}, {"color": "#97c2fc", "id": "Treatment-Emergent SAEs", "label": "Treatment-Emergent SAEs", "shape": "dot", "title": "ObjectNode: Treatment-Emergent SAEs"}, {"color": "#97c2fc", "id": "CDASI score change", "label": "CDASI score change", "shape": "dot", "title": "ObjectNode: CDASI score change"}, {"color": "#97c2fc", "id": "Intravenous Sabirnetug", "label": "Intravenous Sabirnetug", "shape": "dot", "title": "ObjectNode: Intravenous Sabirnetug"}, {"color": "#97c2fc", "id": "Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score", "label": "Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score", "shape": "dot", "title": "ObjectNode: Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score"}, {"color": "#97c2fc", "id": "NCT01328093", "label": "NCT01328093", "shape": "dot", "title": "SubjectNode: NCT01328093"}, {"color": "#97c2fc", "id": "Baseline condition", "label": "Baseline condition", "shape": "dot", "title": "ObjectNode: Baseline condition"}, {"color": "#97c2fc", "id": "Simpson Angus Rating Scale", "label": "Simpson Angus Rating Scale", "shape": "dot", "title": "ObjectNode: Simpson Angus Rating Scale"}, {"color": "#97c2fc", "id": "Barnes Akathisia Rating Scale", "label": "Barnes Akathisia Rating Scale", "shape": "dot", "title": "ObjectNode: Barnes Akathisia Rating Scale"}, {"color": "#97c2fc", "id": "Change in weight control", "label": "Change in weight control", "shape": "dot", "title": "ObjectNode: Change in weight control"}, {"color": "#97c2fc", "id": "Iloperidone", "label": "Iloperidone", "shape": "dot", "title": "ObjectNode: Iloperidone"}, {"color": "#97c2fc", "id": "LY2624803", "label": "LY2624803", "shape": "dot", "title": "ObjectNode: LY2624803"}, {"color": "#97c2fc", "id": "Early-Episode Schizophrenia", "label": "Early-Episode Schizophrenia", "shape": "dot", "title": "ObjectNode: Early-Episode Schizophrenia"}, {"color": "#97c2fc", "id": "NCT04732793", "label": "NCT04732793", "shape": "dot", "title": "SubjectNode: NCT04732793"}, {"color": "#97c2fc", "id": "WOMAC A", "label": "WOMAC A", "shape": "dot", "title": "ObjectNode: WOMAC A"}, {"color": "#97c2fc", "id": "baseline through 16 weeks", "label": "baseline through 16 weeks", "shape": "dot", "title": "ObjectNode: baseline through 16 weeks"}, {"color": "#97c2fc", "id": "WOMAC B Stiffness", "label": "WOMAC B Stiffness", "shape": "dot", "title": "ObjectNode: WOMAC B Stiffness"}, {"color": "#97c2fc", "id": "WOMAC A subscale", "label": "WOMAC A subscale", "shape": "dot", "title": "ObjectNode: WOMAC A subscale"}, {"color": "#97c2fc", "id": "Hyruan ONE", "label": "Hyruan ONE", "shape": "dot", "title": "ObjectNode: Hyruan ONE"}, {"color": "#97c2fc", "id": "Osteoarthritis-related Pain", "label": "Osteoarthritis-related Pain", "shape": "dot", "title": "ObjectNode: Osteoarthritis-related Pain"}, {"color": "#97c2fc", "id": "NCT02240693", "label": "NCT02240693", "shape": "dot", "title": "SubjectNode: NCT02240693"}, {"color": "#97c2fc", "id": "Change From Baseline-2", "label": "Change From Baseline-2", "shape": "dot", "title": "ObjectNode: Change From Baseline-2"}, {"color": "#97c2fc", "id": "Early Symptomatic Alzheimer\u0027s Disease", "label": "Early Symptomatic Alzheimer\u0027s Disease", "shape": "dot", "title": "ObjectNode: Early Symptomatic Alzheimer\u0027s Disease"}, {"color": "#97c2fc", "id": "BI 456906", "label": "BI 456906", "shape": "dot", "title": "ObjectNode: BI 456906"}, {"color": "#97c2fc", "id": "self care and daily function", "label": "self care and daily function", "shape": "dot", "title": "ObjectNode: self care and daily function"}, {"color": "#97c2fc", "id": "ADCS-ADL scale", "label": "ADCS-ADL scale", "shape": "dot", "title": "ObjectNode: ADCS-ADL scale"}, {"color": "#97c2fc", "id": "NCT06456593", "label": "NCT06456593", "shape": "dot", "title": "SubjectNode: NCT06456593"}, {"color": "#97c2fc", "id": "SES-CD ulcer subscore \u003e 1", "label": "SES-CD ulcer subscore \u003e 1", "shape": "dot", "title": "ObjectNode: SES-CD ulcer subscore \u003e 1"}, {"color": "#97c2fc", "id": "endoscopic treatment improvement", "label": "endoscopic treatment improvement", "shape": "dot", "title": "ObjectNode: endoscopic treatment improvement"}, {"color": "#97c2fc", "id": "Clinically Significant Remission", "label": "Clinically Significant Remission", "shape": "dot", "title": "ObjectNode: Clinically Significant Remission"}, {"color": "#97c2fc", "id": "CDAI-Defined Clinical Response", "label": "CDAI-Defined Clinical Response", "shape": "dot", "title": "ObjectNode: CDAI-Defined Clinical Response"}, {"color": "#97c2fc", "id": "Weeks 12", "label": "Weeks 12", "shape": "dot", "title": "ObjectNode: Weeks 12"}, {"color": "#97c2fc", "id": "Week 60", "label": "Week 60", "shape": "dot", "title": "ObjectNode: Week 60"}, {"color": "#97c2fc", "id": "Obefazimod", "label": "Obefazimod", "shape": "dot", "title": "ObjectNode: Obefazimod"}, {"color": "#97c2fc", "id": "PRO-2 Remission", "label": "PRO-2 Remission", "shape": "dot", "title": "ObjectNode: PRO-2 Remission"}, {"color": "#97c2fc", "id": "Mayo IBD symptom severity score", "label": "Mayo IBD symptom severity score", "shape": "dot", "title": "ObjectNode: Mayo IBD symptom severity score"}, {"color": "#97c2fc", "id": "Simple Endoscopic Score for Crohn\u0027s disease (SES-CD)", "label": "Simple Endoscopic Score for Crohn\u0027s disease (SES-CD)", "shape": "dot", "title": "ObjectNode: Simple Endoscopic Score for Crohn\u0027s disease (SES-CD)"}, {"color": "#97c2fc", "id": "Immune-related Colitis", "label": "Immune-related Colitis", "shape": "dot", "title": "ObjectNode: Immune-related Colitis"}, {"color": "#97c2fc", "id": "NCT05590793", "label": "NCT05590793", "shape": "dot", "title": "SubjectNode: NCT05590793"}, {"color": "#97c2fc", "id": "Change in electrocardiograms", "label": "Change in electrocardiograms", "shape": "dot", "title": "ObjectNode: Change in electrocardiograms"}, {"color": "#97c2fc", "id": "Serum Testosterone Levels", "label": "Serum Testosterone Levels", "shape": "dot", "title": "ObjectNode: Serum Testosterone Levels"}, {"color": "#97c2fc", "id": "Triptorelin Pamoate PR 3-month", "label": "Triptorelin Pamoate PR 3-month", "shape": "dot", "title": "ObjectNode: Triptorelin Pamoate PR 3-month"}, {"color": "#97c2fc", "id": "Chinese Adult Subjects", "label": "Chinese Adult Subjects", "shape": "dot", "title": "ObjectNode: Chinese Adult Subjects"}, {"color": "#97c2fc", "id": "Advanced Prostate Cancer", "label": "Advanced Prostate Cancer", "shape": "dot", "title": "ObjectNode: Advanced Prostate Cancer"}, {"color": "#97c2fc", "id": "physical examination results", "label": "physical examination results", "shape": "dot", "title": "ObjectNode: physical examination results"}, {"color": "#97c2fc", "id": "Prostate-Specific Antigen Levels", "label": "Prostate-Specific Antigen Levels", "shape": "dot", "title": "ObjectNode: Prostate-Specific Antigen Levels"}, {"color": "#97c2fc", "id": "Clinically significant abnormalities in vital signs", "label": "Clinically significant abnormalities in vital signs", "shape": "dot", "title": "ObjectNode: Clinically significant abnormalities in vital signs"}, {"color": "#97c2fc", "id": "Screening laboratory parameters", "label": "Screening laboratory parameters", "shape": "dot", "title": "ObjectNode: Screening laboratory parameters"}, {"color": "#97c2fc", "id": "NCT05732454", "label": "NCT05732454", "shape": "dot", "title": "SubjectNode: NCT05732454"}, {"color": "#97c2fc", "id": "Overall platelet response", "label": "Overall platelet response", "shape": "dot", "title": "ObjectNode: Overall platelet response"}, {"color": "#97c2fc", "id": "RBC", "label": "RBC", "shape": "dot", "title": "ObjectNode: RBC"}, {"color": "#97c2fc", "id": "IGA cleared or minimal", "label": "IGA cleared or minimal", "shape": "dot", "title": "ObjectNode: IGA cleared or minimal"}, {"color": "#97c2fc", "id": "Urea Nitrogen", "label": "Urea Nitrogen", "shape": "dot", "title": "ObjectNode: Urea Nitrogen"}, {"color": "#97c2fc", "id": "oral medications", "label": "oral medications", "shape": "dot", "title": "ObjectNode: oral medications"}, {"color": "#97c2fc", "id": "Mean Change Total Bilirubin", "label": "Mean Change Total Bilirubin", "shape": "dot", "title": "ObjectNode: Mean Change Total Bilirubin"}, {"color": "#97c2fc", "id": "mean corpuscular hemoglobin", "label": "mean corpuscular hemoglobin", "shape": "dot", "title": "ObjectNode: mean corpuscular hemoglobin"}, {"color": "#97c2fc", "id": "TBNK panel", "label": "TBNK panel", "shape": "dot", "title": "ObjectNode: TBNK panel"}, {"color": "#97c2fc", "id": "WBC", "label": "WBC", "shape": "dot", "title": "ObjectNode: WBC"}, {"color": "#97c2fc", "id": "Children with atopic dermatitis", "label": "Children with atopic dermatitis", "shape": "dot", "title": "ObjectNode: Children with atopic dermatitis"}, {"color": "#97c2fc", "id": "Oral Etrasimod", "label": "Oral Etrasimod", "shape": "dot", "title": "ObjectNode: Oral Etrasimod"}, {"color": "#97c2fc", "id": "Serum creatinine \u22643 mg/dL", "label": "Serum creatinine \u22643 mg/dL", "shape": "dot", "title": "ObjectNode: Serum creatinine \u22643 mg/dL"}, {"color": "#97c2fc", "id": "Hematocrit change", "label": "Hematocrit change", "shape": "dot", "title": "ObjectNode: Hematocrit change"}, {"color": "#97c2fc", "id": "NCT02220933", "label": "NCT02220933", "shape": "dot", "title": "SubjectNode: NCT02220933"}, {"color": "#97c2fc", "id": "EDSS or TW25", "label": "EDSS or TW25", "shape": "dot", "title": "ObjectNode: EDSS or TW25"}, {"color": "#97c2fc", "id": "Disease duration of secondary progressive multiple sclerosis", "label": "Disease duration of secondary progressive multiple sclerosis", "shape": "dot", "title": "ObjectNode: Disease duration of secondary progressive multiple sclerosis"}, {"color": "#97c2fc", "id": "MSWS", "label": "MSWS", "shape": "dot", "title": "ObjectNode: MSWS"}, {"color": "#97c2fc", "id": "MD1003", "label": "MD1003", "shape": "dot", "title": "ObjectNode: MD1003"}, {"color": "#97c2fc", "id": "decreased EDSS", "label": "decreased EDSS", "shape": "dot", "title": "ObjectNode: decreased EDSS"}, {"color": "#97c2fc", "id": "NCT03836287", "label": "NCT03836287", "shape": "dot", "title": "SubjectNode: NCT03836287"}, {"color": "#97c2fc", "id": "Hyperhidrosis severity 3 or 4", "label": "Hyperhidrosis severity 3 or 4", "shape": "dot", "title": "ObjectNode: Hyperhidrosis severity 3 or 4"}, {"color": "#97c2fc", "id": "Sofpironium Bromide Gel", "label": "Sofpironium Bromide Gel", "shape": "dot", "title": "ObjectNode: Sofpironium Bromide Gel"}, {"color": "#97c2fc", "id": "Gravimetrically Measured Sweat Production", "label": "Gravimetrically Measured Sweat Production", "shape": "dot", "title": "ObjectNode: Gravimetrically Measured Sweat Production"}, {"color": "#97c2fc", "id": "Primary Axillary Hyperhidrosis", "label": "Primary Axillary Hyperhidrosis", "shape": "dot", "title": "ObjectNode: Primary Axillary Hyperhidrosis"}, {"color": "#97c2fc", "id": "Up to 32 weeks", "label": "Up to 32 weeks", "shape": "dot", "title": "ObjectNode: Up to 32 weeks"}, {"color": "#97c2fc", "id": "NCT03068754", "label": "NCT03068754", "shape": "dot", "title": "SubjectNode: NCT03068754"}, {"color": "#97c2fc", "id": "Clinically Significant Response", "label": "Clinically Significant Response", "shape": "dot", "title": "ObjectNode: Clinically Significant Response"}, {"color": "#97c2fc", "id": "Lung function parameters", "label": "Lung function parameters", "shape": "dot", "title": "ObjectNode: Lung function parameters"}, {"color": "#97c2fc", "id": "Acthar Gel", "label": "Acthar Gel", "shape": "dot", "title": "ObjectNode: Acthar Gel"}, {"color": "#97c2fc", "id": "Rasch Overall ALS Disability Scale", "label": "Rasch Overall ALS Disability Scale", "shape": "dot", "title": "ObjectNode: Rasch Overall ALS Disability Scale"}, {"color": "#97c2fc", "id": "ALS or MS", "label": "ALS or MS", "shape": "dot", "title": "ObjectNode: ALS or MS"}, {"color": "#97c2fc", "id": "NCT06272487", "label": "NCT06272487", "shape": "dot", "title": "SubjectNode: NCT06272487"}, {"color": "#97c2fc", "id": "Diagnosis of severe hypertension", "label": "Diagnosis of severe hypertension", "shape": "dot", "title": "ObjectNode: Diagnosis of severe hypertension"}, {"color": "#97c2fc", "id": "Zilebesiran", "label": "Zilebesiran", "shape": "dot", "title": "ObjectNode: Zilebesiran"}, {"color": "#97c2fc", "id": "Standard of Care", "label": "Standard of Care", "shape": "dot", "title": "ObjectNode: Standard of Care"}, {"color": "#97c2fc", "id": "Percent Change from Baseline in Serum Angiotensinogen", "label": "Percent Change from Baseline in Serum Angiotensinogen", "shape": "dot", "title": "ObjectNode: Percent Change from Baseline in Serum Angiotensinogen"}, {"color": "#97c2fc", "id": "NCT02438787", "label": "NCT02438787", "shape": "dot", "title": "SubjectNode: NCT02438787"}, {"color": "#97c2fc", "id": "ASAS20 treatment response", "label": "ASAS20 treatment response", "shape": "dot", "title": "ObjectNode: ASAS20 treatment response"}, {"color": "#97c2fc", "id": "Prior Anti-TNF Therapy", "label": "Prior Anti-TNF Therapy", "shape": "dot", "title": "ObjectNode: Prior Anti-TNF Therapy"}, {"color": "#97c2fc", "id": "Early Spondyloarthritis", "label": "Early Spondyloarthritis", "shape": "dot", "title": "ObjectNode: Early Spondyloarthritis"}, {"color": "#97c2fc", "id": "Abrilumab", "label": "Abrilumab", "shape": "dot", "title": "ObjectNode: Abrilumab"}, {"color": "#97c2fc", "id": "ASAS40 treatment response", "label": "ASAS40 treatment response", "shape": "dot", "title": "ObjectNode: ASAS40 treatment response"}, {"color": "#97c2fc", "id": "NCT04053387", "label": "NCT04053387", "shape": "dot", "title": "SubjectNode: NCT04053387"}, {"color": "#97c2fc", "id": "Median Time to Improvement", "label": "Median Time to Improvement", "shape": "dot", "title": "ObjectNode: Median Time to Improvement"}, {"color": "#97c2fc", "id": "at least one psoriatic plaque", "label": "at least one psoriatic plaque", "shape": "dot", "title": "ObjectNode: at least one psoriatic plaque"}, {"color": "#97c2fc", "id": "sPGA (0)", "label": "sPGA (0)", "shape": "dot", "title": "ObjectNode: sPGA (0)"}, {"color": "#97c2fc", "id": "VTAMA (Tapinarof) Cream", "label": "VTAMA (Tapinarof) Cream", "shape": "dot", "title": "ObjectNode: VTAMA (Tapinarof) Cream"}, {"color": "#97c2fc", "id": "Potentially Clinically Important Changes", "label": "Potentially Clinically Important Changes", "shape": "dot", "title": "ObjectNode: Potentially Clinically Important Changes"}, {"color": "#97c2fc", "id": "NCT05002933", "label": "NCT05002933", "shape": "dot", "title": "SubjectNode: NCT05002933"}, {"color": "#97c2fc", "id": "Adults \u003e=12 years old", "label": "Adults \u003e=12 years old", "shape": "dot", "title": "ObjectNode: Adults \u003e=12 years old"}, {"color": "#97c2fc", "id": "Overweight and Obese Subjects With Type 2 Diabetes", "label": "Overweight and Obese Subjects With Type 2 Diabetes", "shape": "dot", "title": "ObjectNode: Overweight and Obese Subjects With Type 2 Diabetes"}, {"color": "#97c2fc", "id": "Percentage of Participants Achieving a Therapeutic Glycemic Response", "label": "Percentage of Participants Achieving a Therapeutic Glycemic Response", "shape": "dot", "title": "ObjectNode: Percentage of Participants Achieving a Therapeutic Glycemic Response"}, {"color": "#97c2fc", "id": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "label": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "shape": "dot", "title": "ObjectNode: Insulin Glargine/Lixisenatide Fixed Ratio Combination"}, {"color": "#97c2fc", "id": "Adjusted Mean Change HbA1c", "label": "Adjusted Mean Change HbA1c", "shape": "dot", "title": "ObjectNode: Adjusted Mean Change HbA1c"}, {"color": "#97c2fc", "id": "NCT05426733", "label": "NCT05426733", "shape": "dot", "title": "SubjectNode: NCT05426733"}, {"color": "#97c2fc", "id": "Change mid-arm circumference", "label": "Change mid-arm circumference", "shape": "dot", "title": "ObjectNode: Change mid-arm circumference"}, {"color": "#97c2fc", "id": "Change serum bile acids", "label": "Change serum bile acids", "shape": "dot", "title": "ObjectNode: Change serum bile acids"}, {"color": "#97c2fc", "id": "Primary Biliary Cholangitis", "label": "Primary Biliary Cholangitis", "shape": "dot", "title": "ObjectNode: Primary Biliary Cholangitis"}, {"color": "#97c2fc", "id": "Odevixibat", "label": "Odevixibat", "shape": "dot", "title": "ObjectNode: Odevixibat"}, {"color": "#97c2fc", "id": "Change in Fibrosis-4 (FIB-4) Score", "label": "Change in Fibrosis-4 (FIB-4) Score", "shape": "dot", "title": "ObjectNode: Change in Fibrosis-4 (FIB-4) Score"}, {"color": "#97c2fc", "id": "Change pediatric end-stage liver disease score", "label": "Change pediatric end-stage liver disease score", "shape": "dot", "title": "ObjectNode: Change pediatric end-stage liver disease score"}, {"color": "#97c2fc", "id": "Change AST to platelet ratio index", "label": "Change AST to platelet ratio index", "shape": "dot", "title": "ObjectNode: Change AST to platelet ratio index"}, {"color": "#97c2fc", "id": "Proportion alive", "label": "Proportion alive", "shape": "dot", "title": "ObjectNode: Proportion alive"}, {"color": "#97c2fc", "id": "Completion of 104-week Treatment Period", "label": "Completion of 104-week Treatment Period", "shape": "dot", "title": "ObjectNode: Completion of 104-week Treatment Period"}, {"color": "#97c2fc", "id": "Patient\u0027s written informed consent", "label": "Patient\u0027s written informed consent", "shape": "dot", "title": "ObjectNode: Patient\u0027s written informed consent"}, {"color": "#97c2fc", "id": "Change height", "label": "Change height", "shape": "dot", "title": "ObjectNode: Change height"}, {"color": "#97c2fc", "id": "Time to onset sentinel events", "label": "Time to onset sentinel events", "shape": "dot", "title": "ObjectNode: Time to onset sentinel events"}, {"color": "#97c2fc", "id": "NCT04437433", "label": "NCT04437433", "shape": "dot", "title": "SubjectNode: NCT04437433"}, {"color": "#97c2fc", "id": "Columbia Suicide Severity Rating Scale", "label": "Columbia Suicide Severity Rating Scale", "shape": "dot", "title": "ObjectNode: Columbia Suicide Severity Rating Scale"}, {"color": "#97c2fc", "id": "Number of patients with clinically significant changes in vital signs", "label": "Number of patients with clinically significant changes in vital signs", "shape": "dot", "title": "ObjectNode: Number of patients with clinically significant changes in vital signs"}, {"color": "#97c2fc", "id": "Migraine Headaches", "label": "Migraine Headaches", "shape": "dot", "title": "ObjectNode: Migraine Headaches"}, {"color": "#97c2fc", "id": "Clinically significant abnormalities in clinical laboratory values", "label": "Clinically significant abnormalities in clinical laboratory values", "shape": "dot", "title": "ObjectNode: Clinically significant abnormalities in clinical laboratory values"}, {"color": "#97c2fc", "id": "Completed all visits", "label": "Completed all visits", "shape": "dot", "title": "ObjectNode: Completed all visits"}, {"color": "#97c2fc", "id": "Oral Atogepant", "label": "Oral Atogepant", "shape": "dot", "title": "ObjectNode: Oral Atogepant"}, {"color": "#97c2fc", "id": "Clinically significant abnormalities in ECG", "label": "Clinically significant abnormalities in ECG", "shape": "dot", "title": "ObjectNode: Clinically significant abnormalities in ECG"}, {"color": "#97c2fc", "id": "NCT04479787", "label": "NCT04479787", "shape": "dot", "title": "SubjectNode: NCT04479787"}, {"color": "#97c2fc", "id": "Responder Rate PGIC", "label": "Responder Rate PGIC", "shape": "dot", "title": "ObjectNode: Responder Rate PGIC"}, {"color": "#97c2fc", "id": "NRS mean change", "label": "NRS mean change", "shape": "dot", "title": "ObjectNode: NRS mean change"}, {"color": "#97c2fc", "id": "Change in Back Pain", "label": "Change in Back Pain", "shape": "dot", "title": "ObjectNode: Change in Back Pain"}, {"color": "#97c2fc", "id": "10 kHz Spinal Cord Stimulation", "label": "10 kHz Spinal Cord Stimulation", "shape": "dot", "title": "ObjectNode: 10 kHz Spinal Cord Stimulation"}, {"color": "#97c2fc", "id": "\u2265 30% decrease from baseline", "label": "\u2265 30% decrease from baseline", "shape": "dot", "title": "ObjectNode: \u2265 30% decrease from baseline"}, {"color": "#97c2fc", "id": "Change in OSDI", "label": "Change in OSDI", "shape": "dot", "title": "ObjectNode: Change in OSDI"}, {"color": "#97c2fc", "id": "Study Composite Responder", "label": "Study Composite Responder", "shape": "dot", "title": "ObjectNode: Study Composite Responder"}, {"color": "#97c2fc", "id": "Medical Management", "label": "Medical Management", "shape": "dot", "title": "ObjectNode: Medical Management"}, {"color": "#97c2fc", "id": "NCT00327587", "label": "NCT00327587", "shape": "dot", "title": "SubjectNode: NCT00327587"}, {"color": "#97c2fc", "id": "Olmesartan and Amlodipine", "label": "Olmesartan and Amlodipine", "shape": "dot", "title": "ObjectNode: Olmesartan and Amlodipine"}, {"color": "#97c2fc", "id": "Systolic BP control", "label": "Systolic BP control", "shape": "dot", "title": "ObjectNode: Systolic BP control"}, {"color": "#97c2fc", "id": "Diastolic BP \u226590 mmHg", "label": "Diastolic BP \u226590 mmHg", "shape": "dot", "title": "ObjectNode: Diastolic BP \u226590 mmHg"}, {"color": "#97c2fc", "id": "Normalized blood pressure", "label": "Normalized blood pressure", "shape": "dot", "title": "ObjectNode: Normalized blood pressure"}, {"color": "#97c2fc", "id": "Systolic BP \u2265140 mmHg", "label": "Systolic BP \u2265140 mmHg", "shape": "dot", "title": "ObjectNode: Systolic BP \u2265140 mmHg"}, {"color": "#97c2fc", "id": "Diastolic BP \u226580 mmHg", "label": "Diastolic BP \u226580 mmHg", "shape": "dot", "title": "ObjectNode: Diastolic BP \u226580 mmHg"}, {"color": "#97c2fc", "id": "Arm circumference \u003e 42 cm", "label": "Arm circumference \u003e 42 cm", "shape": "dot", "title": "ObjectNode: Arm circumference \u003e 42 cm"}, {"color": "#97c2fc", "id": "Amlodipine Besylate/Benazepril", "label": "Amlodipine Besylate/Benazepril", "shape": "dot", "title": "ObjectNode: Amlodipine Besylate/Benazepril"}, {"color": "#97c2fc", "id": "Diastolic blood pressure \u003c 60 mm Hg", "label": "Diastolic blood pressure \u003c 60 mm Hg", "shape": "dot", "title": "ObjectNode: Diastolic blood pressure \u003c 60 mm Hg"}, {"color": "#97c2fc", "id": "HCTZ 25 mg", "label": "HCTZ 25 mg", "shape": "dot", "title": "ObjectNode: HCTZ 25 mg"}, {"color": "#97c2fc", "id": "NCT02618187", "label": "NCT02618187", "shape": "dot", "title": "SubjectNode: NCT02618187"}, {"color": "#97c2fc", "id": "Duration of Ulcerative Colitis", "label": "Duration of Ulcerative Colitis", "shape": "dot", "title": "ObjectNode: Duration of Ulcerative Colitis"}, {"color": "#97c2fc", "id": "SER-214", "label": "SER-214", "shape": "dot", "title": "ObjectNode: SER-214"}, {"color": "#97c2fc", "id": "Microbiota composition analysis", "label": "Microbiota composition analysis", "shape": "dot", "title": "ObjectNode: Microbiota composition analysis"}, {"color": "#97c2fc", "id": "Participants in Remission", "label": "Participants in Remission", "shape": "dot", "title": "ObjectNode: Participants in Remission"}, {"color": "#97c2fc", "id": "9-point modified Mayo score", "label": "9-point modified Mayo score", "shape": "dot", "title": "ObjectNode: 9-point modified Mayo score"}, {"color": "#97c2fc", "id": "NCT01429987", "label": "NCT01429987", "shape": "dot", "title": "SubjectNode: NCT01429987"}, {"color": "#97c2fc", "id": "stool frequency evaluation", "label": "stool frequency evaluation", "shape": "dot", "title": "ObjectNode: stool frequency evaluation"}, {"color": "#97c2fc", "id": "18 to 55 years old", "label": "18 to 55 years old", "shape": "dot", "title": "ObjectNode: 18 to 55 years old"}, {"color": "#97c2fc", "id": "Plecanatide", "label": "Plecanatide", "shape": "dot", "title": "ObjectNode: Plecanatide"}, {"color": "#97c2fc", "id": "12-week CSBM Frequency", "label": "12-week CSBM Frequency", "shape": "dot", "title": "ObjectNode: 12-week CSBM Frequency"}, {"color": "#97c2fc", "id": "IBS-Constipation", "label": "IBS-Constipation", "shape": "dot", "title": "ObjectNode: IBS-Constipation"}, {"color": "#97c2fc", "id": "Straining Score", "label": "Straining Score", "shape": "dot", "title": "ObjectNode: Straining Score"}, {"color": "#97c2fc", "id": "ROME IV criteria", "label": "ROME IV criteria", "shape": "dot", "title": "ObjectNode: ROME IV criteria"}, {"color": "#97c2fc", "id": "NCT04158687", "label": "NCT04158687", "shape": "dot", "title": "SubjectNode: NCT04158687"}, {"color": "#97c2fc", "id": "CP-601", "label": "CP-601", "shape": "dot", "title": "ObjectNode: CP-601"}, {"color": "#97c2fc", "id": "Total Personal and Social Performance", "label": "Total Personal and Social Performance", "shape": "dot", "title": "ObjectNode: Total Personal and Social Performance"}, {"color": "#97c2fc", "id": "CGI-Severity Score", "label": "CGI-Severity Score", "shape": "dot", "title": "ObjectNode: CGI-Severity Score"}, {"color": "#97c2fc", "id": "NCT01862887", "label": "NCT01862887", "shape": "dot", "title": "SubjectNode: NCT01862887"}, {"color": "#97c2fc", "id": "regular alcohol consumption", "label": "regular alcohol consumption", "shape": "dot", "title": "ObjectNode: regular alcohol consumption"}, {"color": "#97c2fc", "id": "clinically significant changes in Electrocardiogram readings", "label": "clinically significant changes in Electrocardiogram readings", "shape": "dot", "title": "ObjectNode: clinically significant changes in Electrocardiogram readings"}, {"color": "#97c2fc", "id": "PF-07038124", "label": "PF-07038124", "shape": "dot", "title": "ObjectNode: PF-07038124"}, {"color": "#97c2fc", "id": "Fmax", "label": "Fmax", "shape": "dot", "title": "ObjectNode: Fmax"}, {"color": "#97c2fc", "id": "Healthy adult male subjects", "label": "Healthy adult male subjects", "shape": "dot", "title": "ObjectNode: Healthy adult male subjects"}, {"color": "#97c2fc", "id": "Healthy male or female", "label": "Healthy male or female", "shape": "dot", "title": "ObjectNode: Healthy male or female"}, {"color": "#97c2fc", "id": "QTcB change", "label": "QTcB change", "shape": "dot", "title": "ObjectNode: QTcB change"}, {"color": "#97c2fc", "id": "clinically significant respiratory", "label": "clinically significant respiratory", "shape": "dot", "title": "ObjectNode: clinically significant respiratory"}, {"color": "#97c2fc", "id": "Time for Cmax", "label": "Time for Cmax", "shape": "dot", "title": "ObjectNode: Time for Cmax"}, {"color": "#97c2fc", "id": "clinically significant allergic disease", "label": "clinically significant allergic disease", "shape": "dot", "title": "ObjectNode: clinically significant allergic disease"}, {"color": "#97c2fc", "id": "severe renal involvement at Screening", "label": "severe renal involvement at Screening", "shape": "dot", "title": "ObjectNode: severe renal involvement at Screening"}, {"color": "#97c2fc", "id": "Total Fat Mass", "label": "Total Fat Mass", "shape": "dot", "title": "ObjectNode: Total Fat Mass"}, {"color": "#97c2fc", "id": "endocrine abnormalities", "label": "endocrine abnormalities", "shape": "dot", "title": "ObjectNode: endocrine abnormalities"}, {"color": "#97c2fc", "id": "psychiatric disease", "label": "psychiatric disease", "shape": "dot", "title": "ObjectNode: psychiatric disease"}, {"color": "#97c2fc", "id": "Mean change in BMI", "label": "Mean change in BMI", "shape": "dot", "title": "ObjectNode: Mean change in BMI"}, {"color": "#97c2fc", "id": "hepatic dysfunction", "label": "hepatic dysfunction", "shape": "dot", "title": "ObjectNode: hepatic dysfunction"}, {"color": "#97c2fc", "id": "neurological disorder", "label": "neurological disorder", "shape": "dot", "title": "ObjectNode: neurological disorder"}, {"color": "#97c2fc", "id": "positive urine drug screen", "label": "positive urine drug screen", "shape": "dot", "title": "ObjectNode: positive urine drug screen"}, {"color": "#97c2fc", "id": "AUC from time zero", "label": "AUC from time zero", "shape": "dot", "title": "ObjectNode: AUC from time zero"}, {"color": "#97c2fc", "id": "Clinically significant haematology assessment abnormalities", "label": "Clinically significant haematology assessment abnormalities", "shape": "dot", "title": "ObjectNode: Clinically significant haematology assessment abnormalities"}, {"color": "#97c2fc", "id": "gastrointestinal abnormalities", "label": "gastrointestinal abnormalities", "shape": "dot", "title": "ObjectNode: gastrointestinal abnormalities"}, {"color": "#97c2fc", "id": "NCT00397033", "label": "NCT00397033", "shape": "dot", "title": "SubjectNode: NCT00397033"}, {"color": "#97c2fc", "id": "PANSS General Psychopathology Subscale", "label": "PANSS General Psychopathology Subscale", "shape": "dot", "title": "ObjectNode: PANSS General Psychopathology Subscale"}, {"color": "#97c2fc", "id": "Greater Than 50% Reduction", "label": "Greater Than 50% Reduction", "shape": "dot", "title": "ObjectNode: Greater Than 50% Reduction"}, {"color": "#97c2fc", "id": "Oral Paliperidone Extended-Release", "label": "Oral Paliperidone Extended-Release", "shape": "dot", "title": "ObjectNode: Oral Paliperidone Extended-Release"}, {"color": "#97c2fc", "id": "NCT04172233", "label": "NCT04172233", "shape": "dot", "title": "SubjectNode: NCT04172233"}, {"color": "#97c2fc", "id": "mPASI-90", "label": "mPASI-90", "shape": "dot", "title": "ObjectNode: mPASI-90"}, {"color": "#97c2fc", "id": "PASI \u2265 12 points", "label": "PASI \u2265 12 points", "shape": "dot", "title": "ObjectNode: PASI \u2265 12 points"}, {"color": "#97c2fc", "id": "AKST1210", "label": "AKST1210", "shape": "dot", "title": "ObjectNode: AKST1210"}, {"color": "#97c2fc", "id": "Change in Physician\u0027s Global Assessment", "label": "Change in Physician\u0027s Global Assessment", "shape": "dot", "title": "ObjectNode: Change in Physician\u0027s Global Assessment"}, {"color": "#97c2fc", "id": "mPASI-75", "label": "mPASI-75", "shape": "dot", "title": "ObjectNode: mPASI-75"}, {"color": "#97c2fc", "id": "10% body surface areas", "label": "10% body surface areas", "shape": "dot", "title": "ObjectNode: 10% body surface areas"}, {"color": "#97c2fc", "id": "Physician\u0027s global assessment scores", "label": "Physician\u0027s global assessment scores", "shape": "dot", "title": "ObjectNode: Physician\u0027s global assessment scores"}, {"color": "#97c2fc", "id": "NCT05522387", "label": "NCT05522387", "shape": "dot", "title": "SubjectNode: NCT05522387"}, {"color": "#97c2fc", "id": "XPro1595", "label": "XPro1595", "shape": "dot", "title": "ObjectNode: XPro1595"}, {"color": "#97c2fc", "id": "Clinical Dementia Rating-Sum of Boxes", "label": "Clinical Dementia Rating-Sum of Boxes", "shape": "dot", "title": "ObjectNode: Clinical Dementia Rating-Sum of Boxes"}, {"color": "#97c2fc", "id": "predefined criteria", "label": "predefined criteria", "shape": "dot", "title": "ObjectNode: predefined criteria"}, {"color": "#97c2fc", "id": "NCT00848354", "label": "NCT00848354", "shape": "dot", "title": "SubjectNode: NCT00848354"}, {"color": "#97c2fc", "id": "ACR20 Responders", "label": "ACR20 Responders", "shape": "dot", "title": "ObjectNode: ACR20 Responders"}, {"color": "#97c2fc", "id": "HAI Score", "label": "HAI Score", "shape": "dot", "title": "ObjectNode: HAI Score"}, {"color": "#97c2fc", "id": "Etokimab", "label": "Etokimab", "shape": "dot", "title": "ObjectNode: Etokimab"}, {"color": "#97c2fc", "id": "SF36 Score", "label": "SF36 Score", "shape": "dot", "title": "ObjectNode: SF36 Score"}, {"color": "#97c2fc", "id": "arthritis pain", "label": "arthritis pain", "shape": "dot", "title": "ObjectNode: arthritis pain"}, {"color": "#97c2fc", "id": "NCT02674633", "label": "NCT02674633", "shape": "dot", "title": "SubjectNode: NCT02674633"}, {"color": "#97c2fc", "id": "ADHD-RS-IV Scores", "label": "ADHD-RS-IV Scores", "shape": "dot", "title": "ObjectNode: ADHD-RS-IV Scores"}, {"color": "#97c2fc", "id": "TOVA API", "label": "TOVA API", "shape": "dot", "title": "ObjectNode: TOVA API"}, {"color": "#97c2fc", "id": "Software", "label": "Software", "shape": "dot", "title": "ObjectNode: Software"}, {"color": "#97c2fc", "id": "DSM-5 diagnostic criteria", "label": "DSM-5 diagnostic criteria", "shape": "dot", "title": "ObjectNode: DSM-5 diagnostic criteria"}, {"color": "#97c2fc", "id": "ADHD-RS change", "label": "ADHD-RS change", "shape": "dot", "title": "ObjectNode: ADHD-RS change"}, {"color": "#97c2fc", "id": "NCT00886587", "label": "NCT00886587", "shape": "dot", "title": "SubjectNode: NCT00886587"}, {"color": "#97c2fc", "id": "device intervention", "label": "device intervention", "shape": "dot", "title": "ObjectNode: device intervention"}, {"color": "#97c2fc", "id": "EASI score at Week 48", "label": "EASI score at Week 48", "shape": "dot", "title": "ObjectNode: EASI score at Week 48"}, {"color": "#97c2fc", "id": "Able to provide informed consent", "label": "Able to provide informed consent", "shape": "dot", "title": "ObjectNode: Able to provide informed consent"}, {"color": "#97c2fc", "id": "Diagnosis of AD/ADRD", "label": "Diagnosis of AD/ADRD", "shape": "dot", "title": "ObjectNode: Diagnosis of AD/ADRD"}, {"color": "#97c2fc", "id": "Itch Score Day 43", "label": "Itch Score Day 43", "shape": "dot", "title": "ObjectNode: Itch Score Day 43"}, {"color": "#97c2fc", "id": "IGADA Score Day 43", "label": "IGADA Score Day 43", "shape": "dot", "title": "ObjectNode: IGADA Score Day 43"}, {"color": "#97c2fc", "id": "Post-menarchal female", "label": "Post-menarchal female", "shape": "dot", "title": "ObjectNode: Post-menarchal female"}, {"color": "#97c2fc", "id": "negative urine pregnancy test result", "label": "negative urine pregnancy test result", "shape": "dot", "title": "ObjectNode: negative urine pregnancy test result"}, {"color": "#97c2fc", "id": "NCT05054387", "label": "NCT05054387", "shape": "dot", "title": "SubjectNode: NCT05054387"}, {"color": "#97c2fc", "id": "eGFR \u003e 60 ml/min/1.73 m2", "label": "eGFR \u003e 60 ml/min/1.73 m2", "shape": "dot", "title": "ObjectNode: eGFR \u003e 60 ml/min/1.73 m2"}, {"color": "#97c2fc", "id": "12 years or older", "label": "12 years or older", "shape": "dot", "title": "ObjectNode: 12 years or older"}, {"color": "#97c2fc", "id": "plasma or leukocyte \u03b1GAL activity deficient", "label": "plasma or leukocyte \u03b1GAL activity deficient", "shape": "dot", "title": "ObjectNode: plasma or leukocyte \u03b1GAL activity deficient"}, {"color": "#97c2fc", "id": "Fabrazyme", "label": "Fabrazyme", "shape": "dot", "title": "ObjectNode: Fabrazyme"}, {"color": "#97c2fc", "id": "diagnosed with Fabry disease", "label": "diagnosed with Fabry disease", "shape": "dot", "title": "ObjectNode: diagnosed with Fabry disease"}, {"color": "#97c2fc", "id": "change of Fabry disease symptoms", "label": "change of Fabry disease symptoms", "shape": "dot", "title": "ObjectNode: change of Fabry disease symptoms"}, {"color": "#97c2fc", "id": "naive to agalsidase beta", "label": "naive to agalsidase beta", "shape": "dot", "title": "ObjectNode: naive to agalsidase beta"}, {"color": "#97c2fc", "id": "NCT04360187", "label": "NCT04360187", "shape": "dot", "title": "SubjectNode: NCT04360187"}, {"color": "#97c2fc", "id": "Serious AEs", "label": "Serious AEs", "shape": "dot", "title": "ObjectNode: Serious AEs"}, {"color": "#97c2fc", "id": "ages 2 years and older", "label": "ages 2 years and older", "shape": "dot", "title": "ObjectNode: ages 2 years and older"}, {"color": "#97c2fc", "id": "Eczema Area and Severity Index (EASI) of \u226512 and \\\u003c48", "label": "Eczema Area and Severity Index (EASI) of \u226512 and \\\u003c48", "shape": "dot", "title": "ObjectNode: Eczema Area and Severity Index (EASI) of \u226512 and \\\u003c48"}, {"color": "#97c2fc", "id": "Crisaborole", "label": "Crisaborole", "shape": "dot", "title": "ObjectNode: Crisaborole"}, {"color": "#97c2fc", "id": "NCT00678587", "label": "NCT00678587", "shape": "dot", "title": "SubjectNode: NCT00678587"}, {"color": "#97c2fc", "id": "Thrombocytopenia", "label": "Thrombocytopenia", "shape": "dot", "title": "ObjectNode: Thrombocytopenia"}, {"color": "#97c2fc", "id": "Hepatobiliary fibrosis", "label": "Hepatobiliary fibrosis", "shape": "dot", "title": "ObjectNode: Hepatobiliary fibrosis"}, {"color": "#97c2fc", "id": "platelet count \u2265 100", "label": "platelet count \u2265 100", "shape": "dot", "title": "ObjectNode: platelet count \u2265 100"}, {"color": "#97c2fc", "id": "Change in bleeding score", "label": "Change in bleeding score", "shape": "dot", "title": "ObjectNode: Change in bleeding score"}, {"color": "#97c2fc", "id": "Platelet transfusion independence", "label": "Platelet transfusion independence", "shape": "dot", "title": "ObjectNode: Platelet transfusion independence"}, {"color": "#97c2fc", "id": "Switched to eltrombopag or romiplostim", "label": "Switched to eltrombopag or romiplostim", "shape": "dot", "title": "ObjectNode: Switched to eltrombopag or romiplostim"}, {"color": "#97c2fc", "id": "NCT01098487", "label": "NCT01098487", "shape": "dot", "title": "SubjectNode: NCT01098487"}, {"color": "#97c2fc", "id": "Collagen Level", "label": "Collagen Level", "shape": "dot", "title": "ObjectNode: Collagen Level"}, {"color": "#97c2fc", "id": "Chronic Immune Thrombocytopenic Purpura", "label": "Chronic Immune Thrombocytopenic Purpura", "shape": "dot", "title": "ObjectNode: Chronic Immune Thrombocytopenic Purpura"}, {"color": "#97c2fc", "id": "MF Grade change", "label": "MF Grade change", "shape": "dot", "title": "ObjectNode: MF Grade change"}, {"color": "#97c2fc", "id": "centrally-reviewed BM biopsy", "label": "centrally-reviewed BM biopsy", "shape": "dot", "title": "ObjectNode: centrally-reviewed BM biopsy"}, {"color": "#97c2fc", "id": "NCT03772587", "label": "NCT03772587", "shape": "dot", "title": "SubjectNode: NCT03772587"}, {"color": "#97c2fc", "id": "Day 1 up to 393", "label": "Day 1 up to 393", "shape": "dot", "title": "ObjectNode: Day 1 up to 393"}, {"color": "#97c2fc", "id": "Number of Participants Reporting TEAEs", "label": "Number of Participants Reporting TEAEs", "shape": "dot", "title": "ObjectNode: Number of Participants Reporting TEAEs"}, {"color": "#97c2fc", "id": "Lambert Eaton Myasthenic Syndrome", "label": "Lambert Eaton Myasthenic Syndrome", "shape": "dot", "title": "ObjectNode: Lambert Eaton Myasthenic Syndrome"}, {"color": "#97c2fc", "id": "Number of SAEs", "label": "Number of SAEs", "shape": "dot", "title": "ObjectNode: Number of SAEs"}, {"color": "#97c2fc", "id": "M2951", "label": "M2951", "shape": "dot", "title": "ObjectNode: M2951"}, {"color": "#97c2fc", "id": "Number of participants with AESI", "label": "Number of participants with AESI", "shape": "dot", "title": "ObjectNode: Number of participants with AESI"}, {"color": "#97c2fc", "id": "NCT00876187", "label": "NCT00876187", "shape": "dot", "title": "SubjectNode: NCT00876187"}, {"color": "#97c2fc", "id": "Daily LBPI Score", "label": "Daily LBPI Score", "shape": "dot", "title": "ObjectNode: Daily LBPI Score"}, {"color": "#97c2fc", "id": "Chronic Low-Back Pain", "label": "Chronic Low-Back Pain", "shape": "dot", "title": "ObjectNode: Chronic Low-Back Pain"}, {"color": "#97c2fc", "id": "Baseline Observation Carried Forward", "label": "Baseline Observation Carried Forward", "shape": "dot", "title": "ObjectNode: Baseline Observation Carried Forward"}, {"color": "#97c2fc", "id": "Patient Global Improvement", "label": "Patient Global Improvement", "shape": "dot", "title": "ObjectNode: Patient Global Improvement"}, {"color": "#97c2fc", "id": "Subcutaneous Tanezumab", "label": "Subcutaneous Tanezumab", "shape": "dot", "title": "ObjectNode: Subcutaneous Tanezumab"}, {"color": "#97c2fc", "id": "QMG Total Score", "label": "QMG Total Score", "shape": "dot", "title": "ObjectNode: QMG Total Score"}, {"color": "#97c2fc", "id": "NCT00660387", "label": "NCT00660387", "shape": "dot", "title": "SubjectNode: NCT00660387"}, {"color": "#97c2fc", "id": "Levodopa/Carbidopa/Entacapone", "label": "Levodopa/Carbidopa/Entacapone", "shape": "dot", "title": "ObjectNode: Levodopa/Carbidopa/Entacapone"}, {"color": "#97c2fc", "id": "Average Daily Normalized \"Off\" Time", "label": "Average Daily Normalized \"Off\" Time", "shape": "dot", "title": "ObjectNode: Average Daily Normalized \"Off\" Time"}, {"color": "#97c2fc", "id": "Average Daily Normalized \"On\" Time", "label": "Average Daily Normalized \"On\" Time", "shape": "dot", "title": "ObjectNode: Average Daily Normalized \"On\" Time"}, {"color": "#97c2fc", "id": "Change From Baseline in Parkinson\u0027s Disease Questionnaire-39 Summary Index Score", "label": "Change From Baseline in Parkinson\u0027s Disease Questionnaire-39 Summary Index Score", "shape": "dot", "title": "ObjectNode: Change From Baseline in Parkinson\u0027s Disease Questionnaire-39 Summary Index Score"}, {"color": "#97c2fc", "id": "early-stage Parkinson\u0027s disease", "label": "early-stage Parkinson\u0027s disease", "shape": "dot", "title": "ObjectNode: early-stage Parkinson\u0027s disease"}, {"color": "#97c2fc", "id": "NCT01255787", "label": "NCT01255787", "shape": "dot", "title": "SubjectNode: NCT01255787"}, {"color": "#97c2fc", "id": "Major Depressive Disorder With Mixed Features", "label": "Major Depressive Disorder With Mixed Features", "shape": "dot", "title": "ObjectNode: Major Depressive Disorder With Mixed Features"}, {"color": "#97c2fc", "id": "Suvorexant", "label": "Suvorexant", "shape": "dot", "title": "ObjectNode: Suvorexant"}, {"color": "#97c2fc", "id": "Baseline value", "label": "Baseline value", "shape": "dot", "title": "ObjectNode: Baseline value"}, {"color": "#97c2fc", "id": "CGI-C Scale Scores", "label": "CGI-C Scale Scores", "shape": "dot", "title": "ObjectNode: CGI-C Scale Scores"}, {"color": "#97c2fc", "id": "MADRS Response Rate", "label": "MADRS Response Rate", "shape": "dot", "title": "ObjectNode: MADRS Response Rate"}, {"color": "#97c2fc", "id": "MADRS total score \u226522", "label": "MADRS total score \u226522", "shape": "dot", "title": "ObjectNode: MADRS total score \u226522"}, {"color": "#97c2fc", "id": "MADRS Remission at Week 8", "label": "MADRS Remission at Week 8", "shape": "dot", "title": "ObjectNode: MADRS Remission at Week 8"}, {"color": "#97c2fc", "id": "NCT00877487", "label": "NCT00877487", "shape": "dot", "title": "SubjectNode: NCT00877487"}, {"color": "#97c2fc", "id": "Concerta", "label": "Concerta", "shape": "dot", "title": "ObjectNode: Concerta"}, {"color": "#97c2fc", "id": "documented ADHD diagnosis", "label": "documented ADHD diagnosis", "shape": "dot", "title": "ObjectNode: documented ADHD diagnosis"}, {"color": "#97c2fc", "id": "Documented history of ADHD diagnosis", "label": "Documented history of ADHD diagnosis", "shape": "dot", "title": "ObjectNode: Documented history of ADHD diagnosis"}, {"color": "#97c2fc", "id": "stable SPD489 treatment 6 months", "label": "stable SPD489 treatment 6 months", "shape": "dot", "title": "ObjectNode: stable SPD489 treatment 6 months"}, {"color": "#97c2fc", "id": "NCT01524887", "label": "NCT01524887", "shape": "dot", "title": "SubjectNode: NCT01524887"}, {"color": "#97c2fc", "id": "Change in ADCS-ADL", "label": "Change in ADCS-ADL", "shape": "dot", "title": "ObjectNode: Change in ADCS-ADL"}, {"color": "#97c2fc", "id": "Baseline to \u226420 weeks", "label": "Baseline to \u226420 weeks", "shape": "dot", "title": "ObjectNode: Baseline to \u226420 weeks"}, {"color": "#97c2fc", "id": "ADAS-Cog-11 Scores", "label": "ADAS-Cog-11 Scores", "shape": "dot", "title": "ObjectNode: ADAS-Cog-11 Scores"}, {"color": "#97c2fc", "id": "IGIV", "label": "IGIV", "shape": "dot", "title": "ObjectNode: IGIV"}, {"color": "#97c2fc", "id": "Neuropsychiatry Inventory", "label": "Neuropsychiatry Inventory", "shape": "dot", "title": "ObjectNode: Neuropsychiatry Inventory"}, {"color": "#97c2fc", "id": "NCT01617187", "label": "NCT01617187", "shape": "dot", "title": "SubjectNode: NCT01617187"}, {"color": "#97c2fc", "id": "Pimavanserin", "label": "Pimavanserin", "shape": "dot", "title": "ObjectNode: Pimavanserin"}, {"color": "#97c2fc", "id": "PANSS Responders", "label": "PANSS Responders", "shape": "dot", "title": "ObjectNode: PANSS Responders"}, {"color": "#97c2fc", "id": "NCT03465787", "label": "NCT03465787", "shape": "dot", "title": "SubjectNode: NCT03465787"}, {"color": "#97c2fc", "id": "no prior lurasidone trial", "label": "no prior lurasidone trial", "shape": "dot", "title": "ObjectNode: no prior lurasidone trial"}, {"color": "#97c2fc", "id": "switched from other antipsychotic drugs", "label": "switched from other antipsychotic drugs", "shape": "dot", "title": "ObjectNode: switched from other antipsychotic drugs"}, {"color": "#97c2fc", "id": "age 18 or above and below 65", "label": "age 18 or above and below 65", "shape": "dot", "title": "ObjectNode: age 18 or above and below 65"}, {"color": "#97c2fc", "id": "no drug abuse", "label": "no drug abuse", "shape": "dot", "title": "ObjectNode: no drug abuse"}, {"color": "#97c2fc", "id": "no chronic CNS disease", "label": "no chronic CNS disease", "shape": "dot", "title": "ObjectNode: no chronic CNS disease"}, {"color": "#97c2fc", "id": "no pregnancy or breastfeeding", "label": "no pregnancy or breastfeeding", "shape": "dot", "title": "ObjectNode: no pregnancy or breastfeeding"}, {"color": "#97c2fc", "id": "reasonably good health", "label": "reasonably good health", "shape": "dot", "title": "ObjectNode: reasonably good health"}, {"color": "#97c2fc", "id": "able to cooperate", "label": "able to cooperate", "shape": "dot", "title": "ObjectNode: able to cooperate"}, {"color": "#97c2fc", "id": "NCT05865496", "label": "NCT05865496", "shape": "dot", "title": "SubjectNode: NCT05865496"}, {"color": "#97c2fc", "id": "UPSIT Score", "label": "UPSIT Score", "shape": "dot", "title": "ObjectNode: UPSIT Score"}, {"color": "#97c2fc", "id": "611", "label": "611", "shape": "dot", "title": "ObjectNode: 611"}, {"color": "#97c2fc", "id": "Nasal blockade/obstruction/congestion", "label": "Nasal blockade/obstruction/congestion", "shape": "dot", "title": "ObjectNode: Nasal blockade/obstruction/congestion"}, {"color": "#97c2fc", "id": "Lysholm Score", "label": "Lysholm Score", "shape": "dot", "title": "ObjectNode: Lysholm Score"}, {"color": "#97c2fc", "id": "Nasal polyp score \u2265 4", "label": "Nasal polyp score \u2265 4", "shape": "dot", "title": "ObjectNode: Nasal polyp score \u2265 4"}, {"color": "#97c2fc", "id": "Up to 48 weeks", "label": "Up to 48 weeks", "shape": "dot", "title": "ObjectNode: Up to 48 weeks"}, {"color": "#97c2fc", "id": "Bilateral NPS", "label": "Bilateral NPS", "shape": "dot", "title": "ObjectNode: Bilateral NPS"}, {"color": "#97c2fc", "id": "NCT03909516", "label": "NCT03909516", "shape": "dot", "title": "SubjectNode: NCT03909516"}, {"color": "#97c2fc", "id": "Average Evening Pain Intensity", "label": "Average Evening Pain Intensity", "shape": "dot", "title": "ObjectNode: Average Evening Pain Intensity"}, {"color": "#97c2fc", "id": "Iovera\u00b0 Device", "label": "Iovera\u00b0 Device", "shape": "dot", "title": "ObjectNode: Iovera\u00b0 Device"}, {"color": "#97c2fc", "id": "Single Assessment Numerical Evaluation", "label": "Single Assessment Numerical Evaluation", "shape": "dot", "title": "ObjectNode: Single Assessment Numerical Evaluation"}, {"color": "#97c2fc", "id": "Lateral Ankle Ligament Reconstruction", "label": "Lateral Ankle Ligament Reconstruction", "shape": "dot", "title": "ObjectNode: Lateral Ankle Ligament Reconstruction"}, {"color": "#97c2fc", "id": "Area-Under-Effect", "label": "Area-Under-Effect", "shape": "dot", "title": "ObjectNode: Area-Under-Effect"}, {"color": "#97c2fc", "id": "Baseline to 10 days post-surgery", "label": "Baseline to 10 days post-surgery", "shape": "dot", "title": "ObjectNode: Baseline to 10 days post-surgery"}, {"color": "#97c2fc", "id": "Oxford Knee Score", "label": "Oxford Knee Score", "shape": "dot", "title": "ObjectNode: Oxford Knee Score"}, {"color": "#97c2fc", "id": "NCT03836716", "label": "NCT03836716", "shape": "dot", "title": "SubjectNode: NCT03836716"}, {"color": "#97c2fc", "id": "Hematology Screening parameters", "label": "Hematology Screening parameters", "shape": "dot", "title": "ObjectNode: Hematology Screening parameters"}, {"color": "#97c2fc", "id": "Aramchol Meglumine", "label": "Aramchol Meglumine", "shape": "dot", "title": "ObjectNode: Aramchol Meglumine"}, {"color": "#97c2fc", "id": "Mean Change EASI", "label": "Mean Change EASI", "shape": "dot", "title": "ObjectNode: Mean Change EASI"}, {"color": "#97c2fc", "id": "IMP dose", "label": "IMP dose", "shape": "dot", "title": "ObjectNode: IMP dose"}, {"color": "#97c2fc", "id": "NCT02111096", "label": "NCT02111096", "shape": "dot", "title": "SubjectNode: NCT02111096"}, {"color": "#97c2fc", "id": "Fasting and Post meal Glucose", "label": "Fasting and Post meal Glucose", "shape": "dot", "title": "ObjectNode: Fasting and Post meal Glucose"}, {"color": "#97c2fc", "id": "ALT and AST elevation", "label": "ALT and AST elevation", "shape": "dot", "title": "ObjectNode: ALT and AST elevation"}, {"color": "#97c2fc", "id": "hepatic fat fraction \u2265 5%", "label": "hepatic fat fraction \u2265 5%", "shape": "dot", "title": "ObjectNode: hepatic fat fraction \u2265 5%"}, {"color": "#97c2fc", "id": "Fasting Triglyceride Levels", "label": "Fasting Triglyceride Levels", "shape": "dot", "title": "ObjectNode: Fasting Triglyceride Levels"}, {"color": "#97c2fc", "id": "Baseline Weight", "label": "Baseline Weight", "shape": "dot", "title": "ObjectNode: Baseline Weight"}, {"color": "#97c2fc", "id": "Hemoglobin A1c Levels", "label": "Hemoglobin A1c Levels", "shape": "dot", "title": "ObjectNode: Hemoglobin A1c Levels"}, {"color": "#97c2fc", "id": "NCT02046616", "label": "NCT02046616", "shape": "dot", "title": "SubjectNode: NCT02046616"}, {"color": "#97c2fc", "id": "Change from Baseline in DAS28-CRP", "label": "Change from Baseline in DAS28-CRP", "shape": "dot", "title": "ObjectNode: Change from Baseline in DAS28-CRP"}, {"color": "#97c2fc", "id": "methotrexate-inadequate responders", "label": "methotrexate-inadequate responders", "shape": "dot", "title": "ObjectNode: methotrexate-inadequate responders"}, {"color": "#97c2fc", "id": "Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response", "label": "Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response", "shape": "dot", "title": "ObjectNode: Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response"}, {"color": "#97c2fc", "id": "Tocilizumab Subcutaneous", "label": "Tocilizumab Subcutaneous", "shape": "dot", "title": "ObjectNode: Tocilizumab Subcutaneous"}, {"color": "#97c2fc", "id": "NCT01647516", "label": "NCT01647516", "shape": "dot", "title": "SubjectNode: NCT01647516"}, {"color": "#97c2fc", "id": "Clinical Response 100", "label": "Clinical Response 100", "shape": "dot", "title": "ObjectNode: Clinical Response 100"}, {"color": "#97c2fc", "id": "Ozarelix", "label": "Ozarelix", "shape": "dot", "title": "ObjectNode: Ozarelix"}, {"color": "#97c2fc", "id": "NCT01058096", "label": "NCT01058096", "shape": "dot", "title": "SubjectNode: NCT01058096"}, {"color": "#97c2fc", "id": "Aripiprazole Lauroxil", "label": "Aripiprazole Lauroxil", "shape": "dot", "title": "ObjectNode: Aripiprazole Lauroxil"}, {"color": "#97c2fc", "id": "Adults With Bipolar I Disorder", "label": "Adults With Bipolar I Disorder", "shape": "dot", "title": "ObjectNode: Adults With Bipolar I Disorder"}, {"color": "#97c2fc", "id": "YMRS score", "label": "YMRS score", "shape": "dot", "title": "ObjectNode: YMRS score"}, {"color": "#97c2fc", "id": "CGI-Improvement Score", "label": "CGI-Improvement Score", "shape": "dot", "title": "ObjectNode: CGI-Improvement Score"}, {"color": "#97c2fc", "id": "NCT02317016", "label": "NCT02317016", "shape": "dot", "title": "SubjectNode: NCT02317016"}, {"color": "#97c2fc", "id": "AUC of Rosuvastatin", "label": "AUC of Rosuvastatin", "shape": "dot", "title": "ObjectNode: AUC of Rosuvastatin"}, {"color": "#97c2fc", "id": "AZD9668", "label": "AZD9668", "shape": "dot", "title": "ObjectNode: AZD9668"}, {"color": "#97c2fc", "id": "tmax of rosuvastatin", "label": "tmax of rosuvastatin", "shape": "dot", "title": "ObjectNode: tmax of rosuvastatin"}, {"color": "#97c2fc", "id": "Maximally Tolerated Statin", "label": "Maximally Tolerated Statin", "shape": "dot", "title": "ObjectNode: Maximally Tolerated Statin"}, {"color": "#97c2fc", "id": "Metastatic Non-squamous Non-Small-Cell Lung Cancer", "label": "Metastatic Non-squamous Non-Small-Cell Lung Cancer", "shape": "dot", "title": "ObjectNode: Metastatic Non-squamous Non-Small-Cell Lung Cancer"}, {"color": "#97c2fc", "id": "NCT04839016", "label": "NCT04839016", "shape": "dot", "title": "SubjectNode: NCT04839016"}, {"color": "#97c2fc", "id": "inadequately controlled by topical treatment", "label": "inadequately controlled by topical treatment", "shape": "dot", "title": "ObjectNode: inadequately controlled by topical treatment"}, {"color": "#97c2fc", "id": "PASI-75 Score", "label": "PASI-75 Score", "shape": "dot", "title": "ObjectNode: PASI-75 Score"}, {"color": "#97c2fc", "id": "sPGA of Clear or Almost Clear at Week 16", "label": "sPGA of Clear or Almost Clear at Week 16", "shape": "dot", "title": "ObjectNode: sPGA of Clear or Almost Clear at Week 16"}, {"color": "#97c2fc", "id": "disease inadequately controlled", "label": "disease inadequately controlled", "shape": "dot", "title": "ObjectNode: disease inadequately controlled"}, {"color": "#97c2fc", "id": "inadequate topical response", "label": "inadequate topical response", "shape": "dot", "title": "ObjectNode: inadequate topical response"}, {"color": "#97c2fc", "id": "BSA score \u2265 10%", "label": "BSA score \u2265 10%", "shape": "dot", "title": "ObjectNode: BSA score \u2265 10%"}, {"color": "#97c2fc", "id": "PASI-75 at Week 24", "label": "PASI-75 at Week 24", "shape": "dot", "title": "ObjectNode: PASI-75 at Week 24"}, {"color": "#97c2fc", "id": "Mild to Severe Plaque Psoriasis", "label": "Mild to Severe Plaque Psoriasis", "shape": "dot", "title": "ObjectNode: Mild to Severe Plaque Psoriasis"}, {"color": "#97c2fc", "id": "sPGA score \u2265 3 points", "label": "sPGA score \u2265 3 points", "shape": "dot", "title": "ObjectNode: sPGA score \u2265 3 points"}, {"color": "#97c2fc", "id": "SHR0302", "label": "SHR0302", "shape": "dot", "title": "ObjectNode: SHR0302"}, {"color": "#97c2fc", "id": "NCT03971422", "label": "NCT03971422", "shape": "dot", "title": "SubjectNode: NCT03971422"}, {"color": "#97c2fc", "id": "Baseline up to Day 21", "label": "Baseline up to Day 21", "shape": "dot", "title": "ObjectNode: Baseline up to Day 21"}, {"color": "#97c2fc", "id": "Romosozumab", "label": "Romosozumab", "shape": "dot", "title": "ObjectNode: Romosozumab"}, {"color": "#97c2fc", "id": "Percentage of Participants Achieving MG-ADL Response", "label": "Percentage of Participants Achieving MG-ADL Response", "shape": "dot", "title": "ObjectNode: Percentage of Participants Achieving MG-ADL Response"}, {"color": "#97c2fc", "id": "NCT03845075", "label": "NCT03845075", "shape": "dot", "title": "SubjectNode: NCT03845075"}, {"color": "#97c2fc", "id": "Liver function parameters", "label": "Liver function parameters", "shape": "dot", "title": "ObjectNode: Liver function parameters"}, {"color": "#97c2fc", "id": "Metoprolol Succinate Prolonged-Release Tablet", "label": "Metoprolol Succinate Prolonged-Release Tablet", "shape": "dot", "title": "ObjectNode: Metoprolol Succinate Prolonged-Release Tablet"}, {"color": "#97c2fc", "id": "Number of Participants With Any Treatment-Emergent Adverse Events", "label": "Number of Participants With Any Treatment-Emergent Adverse Events", "shape": "dot", "title": "ObjectNode: Number of Participants With Any Treatment-Emergent Adverse Events"}, {"color": "#97c2fc", "id": "Acquired Hypothalamic Obesity", "label": "Acquired Hypothalamic Obesity", "shape": "dot", "title": "ObjectNode: Acquired Hypothalamic Obesity"}, {"color": "#97c2fc", "id": "Change from Baseline in Average Heart Rate", "label": "Change from Baseline in Average Heart Rate", "shape": "dot", "title": "ObjectNode: Change from Baseline in Average Heart Rate"}, {"color": "#97c2fc", "id": "Tesofensine", "label": "Tesofensine", "shape": "dot", "title": "ObjectNode: Tesofensine"}, {"color": "#97c2fc", "id": "Serum Creatinine Elevations", "label": "Serum Creatinine Elevations", "shape": "dot", "title": "ObjectNode: Serum Creatinine Elevations"}, {"color": "#97c2fc", "id": "Hematology Laboratory Results", "label": "Hematology Laboratory Results", "shape": "dot", "title": "ObjectNode: Hematology Laboratory Results"}, {"color": "#97c2fc", "id": "NCT04507659", "label": "NCT04507659", "shape": "dot", "title": "SubjectNode: NCT04507659"}, {"color": "#97c2fc", "id": "Sacroiliitis", "label": "Sacroiliitis", "shape": "dot", "title": "ObjectNode: Sacroiliitis"}, {"color": "#97c2fc", "id": "\u2265 20%", "label": "\u2265 20%", "shape": "dot", "title": "ObjectNode: \u2265 20%"}, {"color": "#97c2fc", "id": "ASAS20 response at Week 12", "label": "ASAS20 response at Week 12", "shape": "dot", "title": "ObjectNode: ASAS20 response at Week 12"}, {"color": "#97c2fc", "id": "Jaktinib Hydrochloride Tablets", "label": "Jaktinib Hydrochloride Tablets", "shape": "dot", "title": "ObjectNode: Jaktinib Hydrochloride Tablets"}, {"color": "#97c2fc", "id": "NCT02868359", "label": "NCT02868359", "shape": "dot", "title": "SubjectNode: NCT02868359"}, {"color": "#97c2fc", "id": "Pain scoring", "label": "Pain scoring", "shape": "dot", "title": "ObjectNode: Pain scoring"}, {"color": "#97c2fc", "id": "Pain Interference on Sleep", "label": "Pain Interference on Sleep", "shape": "dot", "title": "ObjectNode: Pain Interference on Sleep"}, {"color": "#97c2fc", "id": "Neck Disability Index Score", "label": "Neck Disability Index Score", "shape": "dot", "title": "ObjectNode: Neck Disability Index Score"}, {"color": "#97c2fc", "id": "Lyrica", "label": "Lyrica", "shape": "dot", "title": "ObjectNode: Lyrica"}, {"color": "#97c2fc", "id": "EuroQol 5 Dimensions 5 Levels", "label": "EuroQol 5 Dimensions 5 Levels", "shape": "dot", "title": "ObjectNode: EuroQol 5 Dimensions 5 Levels"}, {"color": "#97c2fc", "id": "Rescue medication consumption", "label": "Rescue medication consumption", "shape": "dot", "title": "ObjectNode: Rescue medication consumption"}, {"color": "#97c2fc", "id": "NCT01649375", "label": "NCT01649375", "shape": "dot", "title": "SubjectNode: NCT01649375"}, {"color": "#97c2fc", "id": "securkinumab", "label": "securkinumab", "shape": "dot", "title": "ObjectNode: securkinumab"}, {"color": "#97c2fc", "id": "high-sensitivity CRP", "label": "high-sensitivity CRP", "shape": "dot", "title": "ObjectNode: high-sensitivity CRP"}, {"color": "#97c2fc", "id": "NCT00809159", "label": "NCT00809159", "shape": "dot", "title": "SubjectNode: NCT00809159"}, {"color": "#97c2fc", "id": "AIN457", "label": "AIN457", "shape": "dot", "title": "ObjectNode: AIN457"}, {"color": "#97c2fc", "id": "Moderate to severe CD", "label": "Moderate to severe CD", "shape": "dot", "title": "ObjectNode: Moderate to severe CD"}, {"color": "#97c2fc", "id": "BASMI Score", "label": "BASMI Score", "shape": "dot", "title": "ObjectNode: BASMI Score"}, {"color": "#97c2fc", "id": "NCT00365859", "label": "NCT00365859", "shape": "dot", "title": "SubjectNode: NCT00365859"}, {"color": "#97c2fc", "id": "screening to week 52/early termination", "label": "screening to week 52/early termination", "shape": "dot", "title": "ObjectNode: screening to week 52/early termination"}, {"color": "#97c2fc", "id": "Autism Spectrum Disorders", "label": "Autism Spectrum Disorders", "shape": "dot", "title": "ObjectNode: Autism Spectrum Disorders"}, {"color": "#97c2fc", "id": "Abnormal Involuntary Movement Scale", "label": "Abnormal Involuntary Movement Scale", "shape": "dot", "title": "ObjectNode: Abnormal Involuntary Movement Scale"}, {"color": "#97c2fc", "id": "NCT04312659", "label": "NCT04312659", "shape": "dot", "title": "SubjectNode: NCT04312659"}, {"color": "#97c2fc", "id": "Children aged 2-15 years", "label": "Children aged 2-15 years", "shape": "dot", "title": "ObjectNode: Children aged 2-15 years"}, {"color": "#97c2fc", "id": "TA-650(Infliximab)", "label": "TA-650(Infliximab)", "shape": "dot", "title": "ObjectNode: TA-650(Infliximab)"}, {"color": "#97c2fc", "id": "Change From Baseline in Height-for-age Z-score", "label": "Change From Baseline in Height-for-age Z-score", "shape": "dot", "title": "ObjectNode: Change From Baseline in Height-for-age Z-score"}, {"color": "#97c2fc", "id": "NCT04098575", "label": "NCT04098575", "shape": "dot", "title": "SubjectNode: NCT04098575"}, {"color": "#97c2fc", "id": "Biphasic Remogliflozin Etabonate", "label": "Biphasic Remogliflozin Etabonate", "shape": "dot", "title": "ObjectNode: Biphasic Remogliflozin Etabonate"}, {"color": "#97c2fc", "id": "NCT04731675", "label": "NCT04731675", "shape": "dot", "title": "SubjectNode: NCT04731675"}, {"color": "#97c2fc", "id": "AMX0035", "label": "AMX0035", "shape": "dot", "title": "ObjectNode: AMX0035"}, {"color": "#97c2fc", "id": "Tenosynovial Giant Cell Tumor of the Knee", "label": "Tenosynovial Giant Cell Tumor of the Knee", "shape": "dot", "title": "ObjectNode: Tenosynovial Giant Cell Tumor of the Knee"}, {"color": "#97c2fc", "id": "WOMAC physical function sub-score", "label": "WOMAC physical function sub-score", "shape": "dot", "title": "ObjectNode: WOMAC physical function sub-score"}, {"color": "#97c2fc", "id": "Overall Tumor Response", "label": "Overall Tumor Response", "shape": "dot", "title": "ObjectNode: Overall Tumor Response"}, {"color": "#97c2fc", "id": "Change in Active Range of Motion", "label": "Change in Active Range of Motion", "shape": "dot", "title": "ObjectNode: Change in Active Range of Motion"}, {"color": "#97c2fc", "id": "NCT03881059", "label": "NCT03881059", "shape": "dot", "title": "SubjectNode: NCT03881059"}, {"color": "#97c2fc", "id": "PASI100 response", "label": "PASI100 response", "shape": "dot", "title": "ObjectNode: PASI100 response"}, {"color": "#97c2fc", "id": "BMS-986231", "label": "BMS-986231", "shape": "dot", "title": "ObjectNode: BMS-986231"}, {"color": "#97c2fc", "id": "History psoriatic arthritis", "label": "History psoriatic arthritis", "shape": "dot", "title": "ObjectNode: History psoriatic arthritis"}, {"color": "#97c2fc", "id": "tender/painful joint count", "label": "tender/painful joint count", "shape": "dot", "title": "ObjectNode: tender/painful joint count"}, {"color": "#97c2fc", "id": "NCT04680975", "label": "NCT04680975", "shape": "dot", "title": "SubjectNode: NCT04680975"}, {"color": "#97c2fc", "id": "Oral Belumosudil", "label": "Oral Belumosudil", "shape": "dot", "title": "ObjectNode: Oral Belumosudil"}, {"color": "#97c2fc", "id": "new onset lung fibrosis", "label": "new onset lung fibrosis", "shape": "dot", "title": "ObjectNode: new onset lung fibrosis"}, {"color": "#97c2fc", "id": "Percent of the predicted forced expiratory volume over 1 second", "label": "Percent of the predicted forced expiratory volume over 1 second", "shape": "dot", "title": "ObjectNode: Percent of the predicted forced expiratory volume over 1 second"}, {"color": "#97c2fc", "id": "current active renal disease", "label": "current active renal disease", "shape": "dot", "title": "ObjectNode: current active renal disease"}, {"color": "#97c2fc", "id": "mRSS", "label": "mRSS", "shape": "dot", "title": "ObjectNode: mRSS"}, {"color": "#97c2fc", "id": "Diffuse Systemic Sclerosis", "label": "Diffuse Systemic Sclerosis", "shape": "dot", "title": "ObjectNode: Diffuse Systemic Sclerosis"}, {"color": "#97c2fc", "id": "cardiac failure", "label": "cardiac failure", "shape": "dot", "title": "ObjectNode: cardiac failure"}, {"color": "#97c2fc", "id": "Pulmonary Vascular Disease", "label": "Pulmonary Vascular Disease", "shape": "dot", "title": "ObjectNode: Pulmonary Vascular Disease"}, {"color": "#97c2fc", "id": "SHAQ-DI", "label": "SHAQ-DI", "shape": "dot", "title": "ObjectNode: SHAQ-DI"}, {"color": "#97c2fc", "id": "ACR CRISS composite score", "label": "ACR CRISS composite score", "shape": "dot", "title": "ObjectNode: ACR CRISS composite score"}, {"color": "#97c2fc", "id": "NCT01603459", "label": "NCT01603459", "shape": "dot", "title": "SubjectNode: NCT01603459"}, {"color": "#97c2fc", "id": "Onabotulinumtoxin A", "label": "Onabotulinumtoxin A", "shape": "dot", "title": "ObjectNode: Onabotulinumtoxin A"}, {"color": "#97c2fc", "id": "Ashworth Score", "label": "Ashworth Score", "shape": "dot", "title": "ObjectNode: Ashworth Score"}, {"color": "#97c2fc", "id": "Post-Stroke Upper Limb Spasticity", "label": "Post-Stroke Upper Limb Spasticity", "shape": "dot", "title": "ObjectNode: Post-Stroke Upper Limb Spasticity"}, {"color": "#97c2fc", "id": "Investigator\u0027s Global Assessment of Efficacy", "label": "Investigator\u0027s Global Assessment of Efficacy", "shape": "dot", "title": "ObjectNode: Investigator\u0027s Global Assessment of Efficacy"}, {"color": "#97c2fc", "id": "Injection Cycle", "label": "Injection Cycle", "shape": "dot", "title": "ObjectNode: Injection Cycle"}, {"color": "#97c2fc", "id": "NCT00614575", "label": "NCT00614575", "shape": "dot", "title": "SubjectNode: NCT00614575"}, {"color": "#97c2fc", "id": "Modified Barthel Index", "label": "Modified Barthel Index", "shape": "dot", "title": "ObjectNode: Modified Barthel Index"}, {"color": "#97c2fc", "id": "UPDRS Part I Item 3 Score", "label": "UPDRS Part I Item 3 Score", "shape": "dot", "title": "ObjectNode: UPDRS Part I Item 3 Score"}, {"color": "#97c2fc", "id": "depressed episode", "label": "depressed episode", "shape": "dot", "title": "ObjectNode: depressed episode"}, {"color": "#97c2fc", "id": "UPDRS Items 32 and 33 Composite Score", "label": "UPDRS Items 32 and 33 Composite Score", "shape": "dot", "title": "ObjectNode: UPDRS Items 32 and 33 Composite Score"}, {"color": "#97c2fc", "id": "Bech Melancholia Subscale Score", "label": "Bech Melancholia Subscale Score", "shape": "dot", "title": "ObjectNode: Bech Melancholia Subscale Score"}, {"color": "#97c2fc", "id": "Pramipexole Extended Release", "label": "Pramipexole Extended Release", "shape": "dot", "title": "ObjectNode: Pramipexole Extended Release"}, {"color": "#97c2fc", "id": "NCT02400775", "label": "NCT02400775", "shape": "dot", "title": "SubjectNode: NCT02400775"}, {"color": "#97c2fc", "id": "Office BP measurements", "label": "Office BP measurements", "shape": "dot", "title": "ObjectNode: Office BP measurements"}, {"color": "#97c2fc", "id": "High LDL-C", "label": "High LDL-C", "shape": "dot", "title": "ObjectNode: High LDL-C"}, {"color": "#97c2fc", "id": "Change in lipid-regulating protein levels", "label": "Change in lipid-regulating protein levels", "shape": "dot", "title": "ObjectNode: Change in lipid-regulating protein levels"}, {"color": "#97c2fc", "id": "Change in calcified component", "label": "Change in calcified component", "shape": "dot", "title": "ObjectNode: Change in calcified component"}, {"color": "#97c2fc", "id": "Change in number of microchannels", "label": "Change in number of microchannels", "shape": "dot", "title": "ObjectNode: Change in number of microchannels"}, {"color": "#97c2fc", "id": "Stage II essential hypertension", "label": "Stage II essential hypertension", "shape": "dot", "title": "ObjectNode: Stage II essential hypertension"}, {"color": "#97c2fc", "id": "Change in thickness of fibrous cap", "label": "Change in thickness of fibrous cap", "shape": "dot", "title": "ObjectNode: Change in thickness of fibrous cap"}, {"color": "#97c2fc", "id": "No recent unstable angina", "label": "No recent unstable angina", "shape": "dot", "title": "ObjectNode: No recent unstable angina"}, {"color": "#97c2fc", "id": "NCT02698475", "label": "NCT02698475", "shape": "dot", "title": "SubjectNode: NCT02698475"}, {"color": "#97c2fc", "id": "C-DLQI Score", "label": "C-DLQI Score", "shape": "dot", "title": "ObjectNode: C-DLQI Score"}, {"color": "#97c2fc", "id": "Failed standard treatment", "label": "Failed standard treatment", "shape": "dot", "title": "ObjectNode: Failed standard treatment"}, {"color": "#97c2fc", "id": "PGA score clear/almost clear", "label": "PGA score clear/almost clear", "shape": "dot", "title": "ObjectNode: PGA score clear/almost clear"}, {"color": "#97c2fc", "id": "NCT01351675", "label": "NCT01351675", "shape": "dot", "title": "SubjectNode: NCT01351675"}, {"color": "#97c2fc", "id": "Time-to-first event", "label": "Time-to-first event", "shape": "dot", "title": "ObjectNode: Time-to-first event"}, {"color": "#97c2fc", "id": "Bardoxolone Methyl", "label": "Bardoxolone Methyl", "shape": "dot", "title": "ObjectNode: Bardoxolone Methyl"}, {"color": "#97c2fc", "id": "Mean change in Systolic BP", "label": "Mean change in Systolic BP", "shape": "dot", "title": "ObjectNode: Mean change in Systolic BP"}, {"color": "#97c2fc", "id": "Time to First Relapse Event", "label": "Time to First Relapse Event", "shape": "dot", "title": "ObjectNode: Time to First Relapse Event"}, {"color": "#97c2fc", "id": "Treatment with an ACE inhibitor and/or an ARB", "label": "Treatment with an ACE inhibitor and/or an ARB", "shape": "dot", "title": "ObjectNode: Treatment with an ACE inhibitor and/or an ARB"}, {"color": "#97c2fc", "id": "Stable Dose Period", "label": "Stable Dose Period", "shape": "dot", "title": "ObjectNode: Stable Dose Period"}]);
edges = new vis.DataSet([{"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Advanced Solid Malignancies"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Hepatitis B e Antigen Seroconversion"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "hypersensitivity itraconazole"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "diagnosed chronic heart failure"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Body weight \u2265 45 kg"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "BMI 18 to 32 kg/m2"}, {"arrows": "to", "from": "NCT03821493", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Maximum Observed Plasma Analyte Concentration"}, {"arrows": "to", "from": "NCT03821493", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "AUCinf of PF-06835919"}, {"arrows": "to", "from": "NCT03821493", "label": "EVALUATES", "title": "EVALUATES", "to": "Isavuconazole"}, {"arrows": "to", "from": "NCT03821493", "label": "INVOLVES", "title": "INVOLVES", "to": "Healthy Fed Participants"}, {"arrows": "to", "from": "NCT04544293", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to Week 49"}, {"arrows": "to", "from": "NCT04544293", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT04544293", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "SGRQ Activity component score"}, {"arrows": "to", "from": "NCT04544293", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "St. George\u0027s Hospital Respiratory Questionnaire"}, {"arrows": "to", "from": "NCT04544293", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change from baseline in Peak FEV1 response"}, {"arrows": "to", "from": "NCT04544293", "label": "EVALUATES", "title": "EVALUATES", "to": "Inhaled Molgramostim Nebulizer Solution"}, {"arrows": "to", "from": "NCT04544293", "label": "INVOLVES", "title": "INVOLVES", "to": "Idiopathic Pulmonary Fibrosis"}, {"arrows": "to", "from": "NCT03181893", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to Week 49"}, {"arrows": "to", "from": "NCT03181893", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT03181893", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "CDASI score change"}, {"arrows": "to", "from": "NCT03181893", "label": "EVALUATES", "title": "EVALUATES", "to": "Intravenous Sabirnetug"}, {"arrows": "to", "from": "NCT03181893", "label": "INVOLVES", "title": "INVOLVES", "to": "Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score"}, {"arrows": "to", "from": "NCT01328093", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline condition"}, {"arrows": "to", "from": "NCT01328093", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Simpson Angus Rating Scale"}, {"arrows": "to", "from": "NCT01328093", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Barnes Akathisia Rating Scale"}, {"arrows": "to", "from": "NCT01328093", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change in weight control"}, {"arrows": "to", "from": "NCT01328093", "label": "EVALUATES", "title": "EVALUATES", "to": "Iloperidone"}, {"arrows": "to", "from": "NCT01328093", "label": "EVALUATES", "title": "EVALUATES", "to": "LY2624803"}, {"arrows": "to", "from": "NCT01328093", "label": "INVOLVES", "title": "INVOLVES", "to": "Early-Episode Schizophrenia"}, {"arrows": "to", "from": "NCT04732793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "WOMAC A"}, {"arrows": "to", "from": "NCT04732793", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "baseline through 16 weeks"}, {"arrows": "to", "from": "NCT04732793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "WOMAC B Stiffness"}, {"arrows": "to", "from": "NCT04732793", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "WOMAC A subscale"}, {"arrows": "to", "from": "NCT04732793", "label": "EVALUATES", "title": "EVALUATES", "to": "Hyruan ONE"}, {"arrows": "to", "from": "NCT04732793", "label": "INVOLVES", "title": "INVOLVES", "to": "Osteoarthritis-related Pain"}, {"arrows": "to", "from": "NCT02240693", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT02240693", "label": "INVOLVES", "title": "INVOLVES", "to": "Early Symptomatic Alzheimer\u0027s Disease"}, {"arrows": "to", "from": "NCT02240693", "label": "EVALUATES", "title": "EVALUATES", "to": "BI 456906"}, {"arrows": "to", "from": "NCT02240693", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "self care and daily function"}, {"arrows": "to", "from": "NCT02240693", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ADCS-ADL scale"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "SES-CD ulcer subscore \u003e 1"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "endoscopic treatment improvement"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically Significant Remission"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CDAI-Defined Clinical Response"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "CDASI score change"}, {"arrows": "to", "from": "NCT06456593", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Weeks 12"}, {"arrows": "to", "from": "NCT06456593", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Week 60"}, {"arrows": "to", "from": "NCT06456593", "label": "EVALUATES", "title": "EVALUATES", "to": "Obefazimod"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PRO-2 Remission"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Mayo IBD symptom severity score"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Simple Endoscopic Score for Crohn\u0027s disease (SES-CD)"}, {"arrows": "to", "from": "NCT06456593", "label": "INVOLVES", "title": "INVOLVES", "to": "Immune-related Colitis"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in electrocardiograms"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Serum Testosterone Levels"}, {"arrows": "to", "from": "NCT05590793", "label": "EVALUATES", "title": "EVALUATES", "to": "Triptorelin Pamoate PR 3-month"}, {"arrows": "to", "from": "NCT05590793", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Chinese Adult Subjects"}, {"arrows": "to", "from": "NCT05590793", "label": "INVOLVES", "title": "INVOLVES", "to": "Advanced Prostate Cancer"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "physical examination results"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Prostate-Specific Antigen Levels"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically significant abnormalities in vital signs"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Screening laboratory parameters"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Overall platelet response"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "RBC"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "IGA cleared or minimal"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Urea Nitrogen"}, {"arrows": "to", "from": "NCT05732454", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "oral medications"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Mean Change Total Bilirubin"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "mean corpuscular hemoglobin"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "TBNK panel"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "WBC"}, {"arrows": "to", "from": "NCT05732454", "label": "INVOLVES", "title": "INVOLVES", "to": "Children with atopic dermatitis"}, {"arrows": "to", "from": "NCT05732454", "label": "EVALUATES", "title": "EVALUATES", "to": "Oral Etrasimod"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Serum creatinine \u22643 mg/dL"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Hematocrit change"}, {"arrows": "to", "from": "NCT02220933", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "EDSS or TW25"}, {"arrows": "to", "from": "NCT02220933", "label": "INVOLVES", "title": "INVOLVES", "to": "Disease duration of secondary progressive multiple sclerosis"}, {"arrows": "to", "from": "NCT02220933", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "MSWS"}, {"arrows": "to", "from": "NCT02220933", "label": "EVALUATES", "title": "EVALUATES", "to": "MD1003"}, {"arrows": "to", "from": "NCT02220933", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "decreased EDSS"}, {"arrows": "to", "from": "NCT03836287", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Hyperhidrosis severity 3 or 4"}, {"arrows": "to", "from": "NCT03836287", "label": "EVALUATES", "title": "EVALUATES", "to": "Sofpironium Bromide Gel"}, {"arrows": "to", "from": "NCT03836287", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Gravimetrically Measured Sweat Production"}, {"arrows": "to", "from": "NCT03836287", "label": "INVOLVES", "title": "INVOLVES", "to": "Primary Axillary Hyperhidrosis"}, {"arrows": "to", "from": "NCT03836287", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Up to 32 weeks"}, {"arrows": "to", "from": "NCT03068754", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Clinically Significant Response"}, {"arrows": "to", "from": "NCT03068754", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Lung function parameters"}, {"arrows": "to", "from": "NCT03068754", "label": "EVALUATES", "title": "EVALUATES", "to": "Acthar Gel"}, {"arrows": "to", "from": "NCT03068754", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Rasch Overall ALS Disability Scale"}, {"arrows": "to", "from": "NCT03068754", "label": "INVOLVES", "title": "INVOLVES", "to": "ALS or MS"}, {"arrows": "to", "from": "NCT06272487", "label": "INVOLVES", "title": "INVOLVES", "to": "Diagnosis of severe hypertension"}, {"arrows": "to", "from": "NCT06272487", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT06272487", "label": "EVALUATES", "title": "EVALUATES", "to": "Zilebesiran"}, {"arrows": "to", "from": "NCT06272487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Standard of Care"}, {"arrows": "to", "from": "NCT06272487", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percent Change from Baseline in Serum Angiotensinogen"}, {"arrows": "to", "from": "NCT02438787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ASAS20 treatment response"}, {"arrows": "to", "from": "NCT02438787", "label": "INVOLVES", "title": "INVOLVES", "to": "Prior Anti-TNF Therapy"}, {"arrows": "to", "from": "NCT02438787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Early Spondyloarthritis"}, {"arrows": "to", "from": "NCT02438787", "label": "EVALUATES", "title": "EVALUATES", "to": "Abrilumab"}, {"arrows": "to", "from": "NCT02438787", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ASAS40 treatment response"}, {"arrows": "to", "from": "NCT04053387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Median Time to Improvement"}, {"arrows": "to", "from": "NCT04053387", "label": "INVOLVES", "title": "INVOLVES", "to": "at least one psoriatic plaque"}, {"arrows": "to", "from": "NCT04053387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "sPGA (0)"}, {"arrows": "to", "from": "NCT04053387", "label": "EVALUATES", "title": "EVALUATES", "to": "VTAMA (Tapinarof) Cream"}, {"arrows": "to", "from": "NCT04053387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Potentially Clinically Important Changes"}, {"arrows": "to", "from": "NCT05002933", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Adults \u003e=12 years old"}, {"arrows": "to", "from": "NCT05002933", "label": "INVOLVES", "title": "INVOLVES", "to": "Overweight and Obese Subjects With Type 2 Diabetes"}, {"arrows": "to", "from": "NCT05002933", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percentage of Participants Achieving a Therapeutic Glycemic Response"}, {"arrows": "to", "from": "NCT05002933", "label": "EVALUATES", "title": "EVALUATES", "to": "Insulin Glargine/Lixisenatide Fixed Ratio Combination"}, {"arrows": "to", "from": "NCT05002933", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Adjusted Mean Change HbA1c"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change mid-arm circumference"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change serum bile acids"}, {"arrows": "to", "from": "NCT05426733", "label": "INVOLVES", "title": "INVOLVES", "to": "Primary Biliary Cholangitis"}, {"arrows": "to", "from": "NCT05426733", "label": "EVALUATES", "title": "EVALUATES", "to": "Odevixibat"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Fibrosis-4 (FIB-4) Score"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change pediatric end-stage liver disease score"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change AST to platelet ratio index"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Proportion alive"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in weight control"}, {"arrows": "to", "from": "NCT05426733", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Completion of 104-week Treatment Period"}, {"arrows": "to", "from": "NCT05426733", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Patient\u0027s written informed consent"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change height"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Time to onset sentinel events"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Columbia Suicide Severity Rating Scale"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Number of patients with clinically significant changes in vital signs"}, {"arrows": "to", "from": "NCT04437433", "label": "INVOLVES", "title": "INVOLVES", "to": "Migraine Headaches"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically significant abnormalities in clinical laboratory values"}, {"arrows": "to", "from": "NCT04437433", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Completed all visits"}, {"arrows": "to", "from": "NCT04437433", "label": "EVALUATES", "title": "EVALUATES", "to": "Oral Atogepant"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically significant abnormalities in ECG"}, {"arrows": "to", "from": "NCT04479787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Responder Rate PGIC"}, {"arrows": "to", "from": "NCT04479787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "NRS mean change"}, {"arrows": "to", "from": "NCT04479787", "label": "INVOLVES", "title": "INVOLVES", "to": "Change in Back Pain"}, {"arrows": "to", "from": "NCT04479787", "label": "EVALUATES", "title": "EVALUATES", "to": "10 kHz Spinal Cord Stimulation"}, {"arrows": "to", "from": "NCT04479787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "\u2265 30% decrease from baseline"}, {"arrows": "to", "from": "NCT04479787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in OSDI"}, {"arrows": "to", "from": "NCT04479787", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Study Composite Responder"}, {"arrows": "to", "from": "NCT04479787", "label": "EVALUATES", "title": "EVALUATES", "to": "Medical Management"}, {"arrows": "to", "from": "NCT00327587", "label": "EVALUATES", "title": "EVALUATES", "to": "Olmesartan and Amlodipine"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Systolic BP control"}, {"arrows": "to", "from": "NCT00327587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Diastolic BP \u226590 mmHg"}, {"arrows": "to", "from": "NCT00327587", "label": "INVOLVES", "title": "INVOLVES", "to": "Diagnosis of severe hypertension"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Normalized blood pressure"}, {"arrows": "to", "from": "NCT00327587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Systolic BP \u2265140 mmHg"}, {"arrows": "to", "from": "NCT00327587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Diastolic BP \u226580 mmHg"}, {"arrows": "to", "from": "NCT00327587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Arm circumference \u003e 42 cm"}, {"arrows": "to", "from": "NCT00327587", "label": "EVALUATES", "title": "EVALUATES", "to": "Amlodipine Besylate/Benazepril"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Diastolic blood pressure \u003c 60 mm Hg"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Diastolic blood pressure \u003c 60 mm Hg"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Systolic BP control"}, {"arrows": "to", "from": "NCT00327587", "label": "EVALUATES", "title": "EVALUATES", "to": "HCTZ 25 mg"}, {"arrows": "to", "from": "NCT02618187", "label": "INVOLVES", "title": "INVOLVES", "to": "Duration of Ulcerative Colitis"}, {"arrows": "to", "from": "NCT02618187", "label": "EVALUATES", "title": "EVALUATES", "to": "SER-214"}, {"arrows": "to", "from": "NCT02618187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Microbiota composition analysis"}, {"arrows": "to", "from": "NCT02618187", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Participants in Remission"}, {"arrows": "to", "from": "NCT02618187", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "9-point modified Mayo score"}, {"arrows": "to", "from": "NCT01429987", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "stool frequency evaluation"}, {"arrows": "to", "from": "NCT01429987", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "18 to 55 years old"}, {"arrows": "to", "from": "NCT01429987", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "BMI 18 to 32 kg/m2"}, {"arrows": "to", "from": "NCT01429987", "label": "EVALUATES", "title": "EVALUATES", "to": "Plecanatide"}, {"arrows": "to", "from": "NCT01429987", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "12-week CSBM Frequency"}, {"arrows": "to", "from": "NCT01429987", "label": "INVOLVES", "title": "INVOLVES", "to": "IBS-Constipation"}, {"arrows": "to", "from": "NCT01429987", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Straining Score"}, {"arrows": "to", "from": "NCT01429987", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "ROME IV criteria"}, {"arrows": "to", "from": "NCT04158687", "label": "EVALUATES", "title": "EVALUATES", "to": "CP-601"}, {"arrows": "to", "from": "NCT04158687", "label": "INVOLVES", "title": "INVOLVES", "to": "Early-Episode Schizophrenia"}, {"arrows": "to", "from": "NCT04158687", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Adults \u003e=12 years old"}, {"arrows": "to", "from": "NCT04158687", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Total Personal and Social Performance"}, {"arrows": "to", "from": "NCT04158687", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-Severity Score"}, {"arrows": "to", "from": "NCT04158687", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "regular alcohol consumption"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "clinically significant changes in Electrocardiogram readings"}, {"arrows": "to", "from": "NCT01862887", "label": "EVALUATES", "title": "EVALUATES", "to": "PF-07038124"}, {"arrows": "to", "from": "NCT01862887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Fmax"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Healthy adult male subjects"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Healthy male or female"}, {"arrows": "to", "from": "NCT01862887", "label": "INVOLVES", "title": "INVOLVES", "to": "QTcB change"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "clinically significant respiratory"}, {"arrows": "to", "from": "NCT01862887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Time for Cmax"}, {"arrows": "to", "from": "NCT01862887", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "QTcB change"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "clinically significant allergic disease"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "severe renal involvement at Screening"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Total Fat Mass"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "endocrine abnormalities"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "psychiatric disease"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Mean change in BMI"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "hepatic dysfunction"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "neurological disorder"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "positive urine drug screen"}, {"arrows": "to", "from": "NCT01862887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "AUC from time zero"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Clinically significant haematology assessment abnormalities"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "gastrointestinal abnormalities"}, {"arrows": "to", "from": "NCT00397033", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "PANSS General Psychopathology Subscale"}, {"arrows": "to", "from": "NCT00397033", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PANSS General Psychopathology Subscale"}, {"arrows": "to", "from": "NCT00397033", "label": "INVOLVES", "title": "INVOLVES", "to": "psychiatric disease"}, {"arrows": "to", "from": "NCT00397033", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Greater Than 50% Reduction"}, {"arrows": "to", "from": "NCT00397033", "label": "EVALUATES", "title": "EVALUATES", "to": "Oral Paliperidone Extended-Release"}, {"arrows": "to", "from": "NCT04172233", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "mPASI-90"}, {"arrows": "to", "from": "NCT04172233", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "PASI \u2265 12 points"}, {"arrows": "to", "from": "NCT04172233", "label": "EVALUATES", "title": "EVALUATES", "to": "AKST1210"}, {"arrows": "to", "from": "NCT04172233", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Physician\u0027s Global Assessment"}, {"arrows": "to", "from": "NCT04172233", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "mPASI-75"}, {"arrows": "to", "from": "NCT04172233", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "10% body surface areas"}, {"arrows": "to", "from": "NCT04172233", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Physician\u0027s global assessment scores"}, {"arrows": "to", "from": "NCT04172233", "label": "INVOLVES", "title": "INVOLVES", "to": "at least one psoriatic plaque"}, {"arrows": "to", "from": "NCT05522387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT05522387", "label": "INVOLVES", "title": "INVOLVES", "to": "Early Symptomatic Alzheimer\u0027s Disease"}, {"arrows": "to", "from": "NCT05522387", "label": "EVALUATES", "title": "EVALUATES", "to": "XPro1595"}, {"arrows": "to", "from": "NCT05522387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinical Dementia Rating-Sum of Boxes"}, {"arrows": "to", "from": "NCT05522387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "predefined criteria"}, {"arrows": "to", "from": "NCT00848354", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ACR20 Responders"}, {"arrows": "to", "from": "NCT00848354", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "HAI Score"}, {"arrows": "to", "from": "NCT00848354", "label": "EVALUATES", "title": "EVALUATES", "to": "Etokimab"}, {"arrows": "to", "from": "NCT00848354", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "SF36 Score"}, {"arrows": "to", "from": "NCT00848354", "label": "INVOLVES", "title": "INVOLVES", "to": "arthritis pain"}, {"arrows": "to", "from": "NCT00848354", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT02674633", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ADHD-RS-IV Scores"}, {"arrows": "to", "from": "NCT02674633", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "TOVA API"}, {"arrows": "to", "from": "NCT02674633", "label": "EVALUATES", "title": "EVALUATES", "to": "Software"}, {"arrows": "to", "from": "NCT02674633", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "DSM-5 diagnostic criteria"}, {"arrows": "to", "from": "NCT02674633", "label": "INVOLVES", "title": "INVOLVES", "to": "ADHD-RS change"}, {"arrows": "to", "from": "NCT00886587", "label": "EVALUATES", "title": "EVALUATES", "to": "device intervention"}, {"arrows": "to", "from": "NCT00886587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "EASI score at Week 48"}, {"arrows": "to", "from": "NCT00886587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Able to provide informed consent"}, {"arrows": "to", "from": "NCT00886587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Diagnosis of AD/ADRD"}, {"arrows": "to", "from": "NCT00886587", "label": "INVOLVES", "title": "INVOLVES", "to": "Children with atopic dermatitis"}, {"arrows": "to", "from": "NCT00886587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Itch Score Day 43"}, {"arrows": "to", "from": "NCT00886587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "IGADA Score Day 43"}, {"arrows": "to", "from": "NCT00886587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Post-menarchal female"}, {"arrows": "to", "from": "NCT00886587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "negative urine pregnancy test result"}, {"arrows": "to", "from": "NCT05054387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "eGFR \u003e 60 ml/min/1.73 m2"}, {"arrows": "to", "from": "NCT05054387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "12 years or older"}, {"arrows": "to", "from": "NCT05054387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "plasma or leukocyte \u03b1GAL activity deficient"}, {"arrows": "to", "from": "NCT05054387", "label": "EVALUATES", "title": "EVALUATES", "to": "Fabrazyme"}, {"arrows": "to", "from": "NCT05054387", "label": "INVOLVES", "title": "INVOLVES", "to": "diagnosed with Fabry disease"}, {"arrows": "to", "from": "NCT05054387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "change of Fabry disease symptoms"}, {"arrows": "to", "from": "NCT05054387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "diagnosed with Fabry disease"}, {"arrows": "to", "from": "NCT05054387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "naive to agalsidase beta"}, {"arrows": "to", "from": "NCT04360187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT04360187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Serious AEs"}, {"arrows": "to", "from": "NCT04360187", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "ages 2 years and older"}, {"arrows": "to", "from": "NCT04360187", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Eczema Area and Severity Index (EASI) of \u226512 and \\\u003c48"}, {"arrows": "to", "from": "NCT04360187", "label": "EVALUATES", "title": "EVALUATES", "to": "Crisaborole"}, {"arrows": "to", "from": "NCT04360187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically Significant Response"}, {"arrows": "to", "from": "NCT04360187", "label": "INVOLVES", "title": "INVOLVES", "to": "Children with atopic dermatitis"}, {"arrows": "to", "from": "NCT00678587", "label": "INVOLVES", "title": "INVOLVES", "to": "Thrombocytopenia"}, {"arrows": "to", "from": "NCT00678587", "label": "INVOLVES", "title": "INVOLVES", "to": "Hepatobiliary fibrosis"}, {"arrows": "to", "from": "NCT00678587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "platelet count \u2265 100"}, {"arrows": "to", "from": "NCT00678587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in bleeding score"}, {"arrows": "to", "from": "NCT00678587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Platelet transfusion independence"}, {"arrows": "to", "from": "NCT00678587", "label": "EVALUATES", "title": "EVALUATES", "to": "Switched to eltrombopag or romiplostim"}, {"arrows": "to", "from": "NCT01098487", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Collagen Level"}, {"arrows": "to", "from": "NCT01098487", "label": "EVALUATES", "title": "EVALUATES", "to": "Switched to eltrombopag or romiplostim"}, {"arrows": "to", "from": "NCT01098487", "label": "INVOLVES", "title": "INVOLVES", "to": "Chronic Immune Thrombocytopenic Purpura"}, {"arrows": "to", "from": "NCT01098487", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "MF Grade change"}, {"arrows": "to", "from": "NCT01098487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "centrally-reviewed BM biopsy"}, {"arrows": "to", "from": "NCT03772587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Day 1 up to 393"}, {"arrows": "to", "from": "NCT03772587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Number of Participants Reporting TEAEs"}, {"arrows": "to", "from": "NCT03772587", "label": "INVOLVES", "title": "INVOLVES", "to": "Lambert Eaton Myasthenic Syndrome"}, {"arrows": "to", "from": "NCT03772587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Number of SAEs"}, {"arrows": "to", "from": "NCT03772587", "label": "EVALUATES", "title": "EVALUATES", "to": "M2951"}, {"arrows": "to", "from": "NCT03772587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Number of participants with AESI"}, {"arrows": "to", "from": "NCT00876187", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Daily LBPI Score"}, {"arrows": "to", "from": "NCT00876187", "label": "INVOLVES", "title": "INVOLVES", "to": "Chronic Low-Back Pain"}, {"arrows": "to", "from": "NCT00876187", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline Observation Carried Forward"}, {"arrows": "to", "from": "NCT00876187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Patient Global Improvement"}, {"arrows": "to", "from": "NCT00876187", "label": "EVALUATES", "title": "EVALUATES", "to": "Subcutaneous Tanezumab"}, {"arrows": "to", "from": "NCT00876187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "QMG Total Score"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT00660387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Levodopa/Carbidopa/Entacapone"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Average Daily Normalized \"Off\" Time"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Average Daily Normalized \"On\" Time"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change From Baseline in Parkinson\u0027s Disease Questionnaire-39 Summary Index Score"}, {"arrows": "to", "from": "NCT00660387", "label": "INVOLVES", "title": "INVOLVES", "to": "early-stage Parkinson\u0027s disease"}, {"arrows": "to", "from": "NCT00660387", "label": "EVALUATES", "title": "EVALUATES", "to": "Levodopa/Carbidopa/Entacapone"}, {"arrows": "to", "from": "NCT01255787", "label": "INVOLVES", "title": "INVOLVES", "to": "Major Depressive Disorder With Mixed Features"}, {"arrows": "to", "from": "NCT01255787", "label": "EVALUATES", "title": "EVALUATES", "to": "Suvorexant"}, {"arrows": "to", "from": "NCT01255787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline value"}, {"arrows": "to", "from": "NCT01255787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT01255787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "MADRS Response Rate"}, {"arrows": "to", "from": "NCT01255787", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "MADRS total score \u226522"}, {"arrows": "to", "from": "NCT01255787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "MADRS Remission at Week 8"}, {"arrows": "to", "from": "NCT00877487", "label": "EVALUATES", "title": "EVALUATES", "to": "Concerta"}, {"arrows": "to", "from": "NCT00877487", "label": "INVOLVES", "title": "INVOLVES", "to": "documented ADHD diagnosis"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Documented history of ADHD diagnosis"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "18 to 55 years old"}, {"arrows": "to", "from": "NCT00877487", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "negative urine pregnancy test result"}, {"arrows": "to", "from": "NCT00877487", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ADHD-RS-IV Scores"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "ADHD-RS-IV Scores"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "stable SPD489 treatment 6 months"}, {"arrows": "to", "from": "NCT01524887", "label": "INVOLVES", "title": "INVOLVES", "to": "Early Symptomatic Alzheimer\u0027s Disease"}, {"arrows": "to", "from": "NCT01524887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in ADCS-ADL"}, {"arrows": "to", "from": "NCT01524887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ADCS-ADL scale"}, {"arrows": "to", "from": "NCT01524887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to \u226420 weeks"}, {"arrows": "to", "from": "NCT01524887", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ADAS-Cog-11 Scores"}, {"arrows": "to", "from": "NCT01524887", "label": "EVALUATES", "title": "EVALUATES", "to": "IGIV"}, {"arrows": "to", "from": "NCT01524887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Neuropsychiatry Inventory"}, {"arrows": "to", "from": "NCT01617187", "label": "EVALUATES", "title": "EVALUATES", "to": "Pimavanserin"}, {"arrows": "to", "from": "NCT01617187", "label": "INVOLVES", "title": "INVOLVES", "to": "Early-Episode Schizophrenia"}, {"arrows": "to", "from": "NCT01617187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT01617187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PANSS Responders"}, {"arrows": "to", "from": "NCT01617187", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT01617187", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "DSM-5 diagnostic criteria"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "CGI-Severity Score"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "no prior lurasidone trial"}, {"arrows": "to", "from": "NCT03465787", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "PANSS General Psychopathology Subscale"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "switched from other antipsychotic drugs"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "age 18 or above and below 65"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "no drug abuse"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "no chronic CNS disease"}, {"arrows": "to", "from": "NCT03465787", "label": "EVALUATES", "title": "EVALUATES", "to": "Iloperidone"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "no pregnancy or breastfeeding"}, {"arrows": "to", "from": "NCT03465787", "label": "INVOLVES", "title": "INVOLVES", "to": "Early-Episode Schizophrenia"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "reasonably good health"}, {"arrows": "to", "from": "NCT03465787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "able to cooperate"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "UPSIT Score"}, {"arrows": "to", "from": "NCT05865496", "label": "EVALUATES", "title": "EVALUATES", "to": "611"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Nasal blockade/obstruction/congestion"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Lysholm Score"}, {"arrows": "to", "from": "NCT05865496", "label": "INVOLVES", "title": "INVOLVES", "to": "Nasal polyp score \u2265 4"}, {"arrows": "to", "from": "NCT05865496", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Up to 48 weeks"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Nasal polyp score \u2265 4"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Bilateral NPS"}, {"arrows": "to", "from": "NCT03909516", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Average Evening Pain Intensity"}, {"arrows": "to", "from": "NCT03909516", "label": "EVALUATES", "title": "EVALUATES", "to": "Iovera\u00b0 Device"}, {"arrows": "to", "from": "NCT03909516", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Single Assessment Numerical Evaluation"}, {"arrows": "to", "from": "NCT03909516", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT03909516", "label": "INVOLVES", "title": "INVOLVES", "to": "Lateral Ankle Ligament Reconstruction"}, {"arrows": "to", "from": "NCT03909516", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Area-Under-Effect"}, {"arrows": "to", "from": "NCT03909516", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 10 days post-surgery"}, {"arrows": "to", "from": "NCT03909516", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Oxford Knee Score"}, {"arrows": "to", "from": "NCT03836716", "label": "INVOLVES", "title": "INVOLVES", "to": "ALS or MS"}, {"arrows": "to", "from": "NCT03836716", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Hematology Screening parameters"}, {"arrows": "to", "from": "NCT03836716", "label": "EVALUATES", "title": "EVALUATES", "to": "Aramchol Meglumine"}, {"arrows": "to", "from": "NCT03836716", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Mean Change EASI"}, {"arrows": "to", "from": "NCT03836716", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "IMP dose"}, {"arrows": "to", "from": "NCT02111096", "label": "INVOLVES", "title": "INVOLVES", "to": "Overweight and Obese Subjects With Type 2 Diabetes"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Fasting and Post meal Glucose"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ALT and AST elevation"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "hepatic fat fraction \u2265 5%"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Fasting Triglyceride Levels"}, {"arrows": "to", "from": "NCT02111096", "label": "EVALUATES", "title": "EVALUATES", "to": "LY2624803"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Baseline Weight"}, {"arrows": "to", "from": "NCT02111096", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Hemoglobin A1c Levels"}, {"arrows": "to", "from": "NCT02046616", "label": "INVOLVES", "title": "INVOLVES", "to": "arthritis pain"}, {"arrows": "to", "from": "NCT02046616", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change from Baseline in DAS28-CRP"}, {"arrows": "to", "from": "NCT02046616", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "methotrexate-inadequate responders"}, {"arrows": "to", "from": "NCT02046616", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response"}, {"arrows": "to", "from": "NCT02046616", "label": "EVALUATES", "title": "EVALUATES", "to": "Tocilizumab Subcutaneous"}, {"arrows": "to", "from": "NCT01647516", "label": "INVOLVES", "title": "INVOLVES", "to": "Duration of Ulcerative Colitis"}, {"arrows": "to", "from": "NCT01647516", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "9-point modified Mayo score"}, {"arrows": "to", "from": "NCT01647516", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Participants in Remission"}, {"arrows": "to", "from": "NCT01647516", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinical Response 100"}, {"arrows": "to", "from": "NCT01647516", "label": "EVALUATES", "title": "EVALUATES", "to": "Ozarelix"}, {"arrows": "to", "from": "NCT01058096", "label": "EVALUATES", "title": "EVALUATES", "to": "Aripiprazole Lauroxil"}, {"arrows": "to", "from": "NCT01058096", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Able to provide informed consent"}, {"arrows": "to", "from": "NCT01058096", "label": "INVOLVES", "title": "INVOLVES", "to": "Adults With Bipolar I Disorder"}, {"arrows": "to", "from": "NCT01058096", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "YMRS score"}, {"arrows": "to", "from": "NCT01058096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-Improvement Score"}, {"arrows": "to", "from": "NCT02317016", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "AUC of Rosuvastatin"}, {"arrows": "to", "from": "NCT02317016", "label": "EVALUATES", "title": "EVALUATES", "to": "AZD9668"}, {"arrows": "to", "from": "NCT02317016", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "tmax of rosuvastatin"}, {"arrows": "to", "from": "NCT02317016", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Maximally Tolerated Statin"}, {"arrows": "to", "from": "NCT02317016", "label": "INVOLVES", "title": "INVOLVES", "to": "Metastatic Non-squamous Non-Small-Cell Lung Cancer"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "inadequately controlled by topical treatment"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "PASI-75 Score"}, {"arrows": "to", "from": "NCT04839016", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "sPGA of Clear or Almost Clear at Week 16"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "disease inadequately controlled"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "12 years or older"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "BMI 18 to 32 kg/m2"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "inadequate topical response"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "BSA score \u2265 10%"}, {"arrows": "to", "from": "NCT04839016", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "PASI-75 at Week 24"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Mild to Severe Plaque Psoriasis"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "sPGA score \u2265 3 points"}, {"arrows": "to", "from": "NCT04839016", "label": "INVOLVES", "title": "INVOLVES", "to": "at least one psoriatic plaque"}, {"arrows": "to", "from": "NCT04839016", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PASI-75 at Week 24"}, {"arrows": "to", "from": "NCT04839016", "label": "EVALUATES", "title": "EVALUATES", "to": "SHR0302"}, {"arrows": "to", "from": "NCT03971422", "label": "INVOLVES", "title": "INVOLVES", "to": "Lambert Eaton Myasthenic Syndrome"}, {"arrows": "to", "from": "NCT03971422", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT03971422", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline up to Day 21"}, {"arrows": "to", "from": "NCT03971422", "label": "EVALUATES", "title": "EVALUATES", "to": "Romosozumab"}, {"arrows": "to", "from": "NCT03971422", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percentage of Participants Achieving MG-ADL Response"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Liver function parameters"}, {"arrows": "to", "from": "NCT03845075", "label": "EVALUATES", "title": "EVALUATES", "to": "Metoprolol Succinate Prolonged-Release Tablet"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Diastolic blood pressure \u003c 60 mm Hg"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Systolic BP control"}, {"arrows": "to", "from": "NCT03845075", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Number of Participants With Any Treatment-Emergent Adverse Events"}, {"arrows": "to", "from": "NCT03845075", "label": "INVOLVES", "title": "INVOLVES", "to": "Acquired Hypothalamic Obesity"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change from Baseline in Average Heart Rate"}, {"arrows": "to", "from": "NCT03845075", "label": "EVALUATES", "title": "EVALUATES", "to": "Tesofensine"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Serious AEs"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Serum Creatinine Elevations"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Hematology Laboratory Results"}, {"arrows": "to", "from": "NCT04507659", "label": "INVOLVES", "title": "INVOLVES", "to": "Sacroiliitis"}, {"arrows": "to", "from": "NCT04507659", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "\u2265 20%"}, {"arrows": "to", "from": "NCT04507659", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ASAS20 response at Week 12"}, {"arrows": "to", "from": "NCT04507659", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ASAS20 response at Week 12"}, {"arrows": "to", "from": "NCT04507659", "label": "EVALUATES", "title": "EVALUATES", "to": "Jaktinib Hydrochloride Tablets"}, {"arrows": "to", "from": "NCT02868359", "label": "INVOLVES", "title": "INVOLVES", "to": "Chronic Low-Back Pain"}, {"arrows": "to", "from": "NCT02868359", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Pain scoring"}, {"arrows": "to", "from": "NCT02868359", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Pain Interference on Sleep"}, {"arrows": "to", "from": "NCT02868359", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Neck Disability Index Score"}, {"arrows": "to", "from": "NCT02868359", "label": "EVALUATES", "title": "EVALUATES", "to": "Lyrica"}, {"arrows": "to", "from": "NCT02868359", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "EuroQol 5 Dimensions 5 Levels"}, {"arrows": "to", "from": "NCT02868359", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Rescue medication consumption"}, {"arrows": "to", "from": "NCT01649375", "label": "EVALUATES", "title": "EVALUATES", "to": "securkinumab"}, {"arrows": "to", "from": "NCT01649375", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT01649375", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ASAS20 treatment response"}, {"arrows": "to", "from": "NCT01649375", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "high-sensitivity CRP"}, {"arrows": "to", "from": "NCT01649375", "label": "INVOLVES", "title": "INVOLVES", "to": "Sacroiliitis"}, {"arrows": "to", "from": "NCT01649375", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ASAS40 treatment response"}, {"arrows": "to", "from": "NCT00809159", "label": "INVOLVES", "title": "INVOLVES", "to": "Sacroiliitis"}, {"arrows": "to", "from": "NCT00809159", "label": "EVALUATES", "title": "EVALUATES", "to": "AIN457"}, {"arrows": "to", "from": "NCT00809159", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ASAS20 treatment response"}, {"arrows": "to", "from": "NCT00809159", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Moderate to severe CD"}, {"arrows": "to", "from": "NCT00809159", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "BASMI Score"}, {"arrows": "to", "from": "NCT00365859", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "screening to week 52/early termination"}, {"arrows": "to", "from": "NCT00365859", "label": "EVALUATES", "title": "EVALUATES", "to": "Iloperidone"}, {"arrows": "to", "from": "NCT00365859", "label": "INVOLVES", "title": "INVOLVES", "to": "Autism Spectrum Disorders"}, {"arrows": "to", "from": "NCT00365859", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Simpson Angus Rating Scale"}, {"arrows": "to", "from": "NCT00365859", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Abnormal Involuntary Movement Scale"}, {"arrows": "to", "from": "NCT04312659", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Participants in Remission"}, {"arrows": "to", "from": "NCT04312659", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Children aged 2-15 years"}, {"arrows": "to", "from": "NCT04312659", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "endoscopic treatment improvement"}, {"arrows": "to", "from": "NCT04312659", "label": "EVALUATES", "title": "EVALUATES", "to": "TA-650(Infliximab)"}, {"arrows": "to", "from": "NCT04312659", "label": "INVOLVES", "title": "INVOLVES", "to": "Immune-related Colitis"}, {"arrows": "to", "from": "NCT04312659", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change From Baseline in Height-for-age Z-score"}, {"arrows": "to", "from": "NCT04312659", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Clinical Response 100"}, {"arrows": "to", "from": "NCT04098575", "label": "INVOLVES", "title": "INVOLVES", "to": "Overweight and Obese Subjects With Type 2 Diabetes"}, {"arrows": "to", "from": "NCT04098575", "label": "EVALUATES", "title": "EVALUATES", "to": "Biphasic Remogliflozin Etabonate"}, {"arrows": "to", "from": "NCT04731675", "label": "EVALUATES", "title": "EVALUATES", "to": "AMX0035"}, {"arrows": "to", "from": "NCT04731675", "label": "INVOLVES", "title": "INVOLVES", "to": "Tenosynovial Giant Cell Tumor of the Knee"}, {"arrows": "to", "from": "NCT04731675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT04731675", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "WOMAC physical function sub-score"}, {"arrows": "to", "from": "NCT04731675", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Overall Tumor Response"}, {"arrows": "to", "from": "NCT04731675", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Active Range of Motion"}, {"arrows": "to", "from": "NCT03881059", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PASI100 response"}, {"arrows": "to", "from": "NCT03881059", "label": "EVALUATES", "title": "EVALUATES", "to": "BMS-986231"}, {"arrows": "to", "from": "NCT03881059", "label": "INVOLVES", "title": "INVOLVES", "to": "History psoriatic arthritis"}, {"arrows": "to", "from": "NCT03881059", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ACR20 Responders"}, {"arrows": "to", "from": "NCT03881059", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "tender/painful joint count"}, {"arrows": "to", "from": "NCT04680975", "label": "EVALUATES", "title": "EVALUATES", "to": "Oral Belumosudil"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Patient Global Improvement"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Physician\u0027s Global Assessment"}, {"arrows": "to", "from": "NCT04680975", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "new onset lung fibrosis"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percent of the predicted forced expiratory volume over 1 second"}, {"arrows": "to", "from": "NCT04680975", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "current active renal disease"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "mRSS"}, {"arrows": "to", "from": "NCT04680975", "label": "INVOLVES", "title": "INVOLVES", "to": "Diffuse Systemic Sclerosis"}, {"arrows": "to", "from": "NCT04680975", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "cardiac failure"}, {"arrows": "to", "from": "NCT04680975", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Pulmonary Vascular Disease"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "SHAQ-DI"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ACR CRISS composite score"}, {"arrows": "to", "from": "NCT01603459", "label": "EVALUATES", "title": "EVALUATES", "to": "Onabotulinumtoxin A"}, {"arrows": "to", "from": "NCT01603459", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Ashworth Score"}, {"arrows": "to", "from": "NCT01603459", "label": "INVOLVES", "title": "INVOLVES", "to": "Post-Stroke Upper Limb Spasticity"}, {"arrows": "to", "from": "NCT01603459", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Investigator\u0027s Global Assessment of Efficacy"}, {"arrows": "to", "from": "NCT01603459", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Injection Cycle"}, {"arrows": "to", "from": "NCT00614575", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Modified Barthel Index"}, {"arrows": "to", "from": "NCT00614575", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "UPDRS Part I Item 3 Score"}, {"arrows": "to", "from": "NCT00614575", "label": "INVOLVES", "title": "INVOLVES", "to": "depressed episode"}, {"arrows": "to", "from": "NCT00614575", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "UPDRS Items 32 and 33 Composite Score"}, {"arrows": "to", "from": "NCT00614575", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Bech Melancholia Subscale Score"}, {"arrows": "to", "from": "NCT00614575", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Weeks 12"}, {"arrows": "to", "from": "NCT00614575", "label": "INVOLVES", "title": "INVOLVES", "to": "early-stage Parkinson\u0027s disease"}, {"arrows": "to", "from": "NCT00614575", "label": "EVALUATES", "title": "EVALUATES", "to": "Pramipexole Extended Release"}, {"arrows": "to", "from": "NCT02400775", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Office BP measurements"}, {"arrows": "to", "from": "NCT02400775", "label": "INVOLVES", "title": "INVOLVES", "to": "High LDL-C"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Fibrosis-4 (FIB-4) Score"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change in lipid-regulating protein levels"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in calcified component"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in number of microchannels"}, {"arrows": "to", "from": "NCT02400775", "label": "INVOLVES", "title": "INVOLVES", "to": "Stage II essential hypertension"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in thickness of fibrous cap"}, {"arrows": "to", "from": "NCT02400775", "label": "INVOLVES", "title": "INVOLVES", "to": "No recent unstable angina"}, {"arrows": "to", "from": "NCT02400775", "label": "EVALUATES", "title": "EVALUATES", "to": "Amlodipine Besylate/Benazepril"}, {"arrows": "to", "from": "NCT02698475", "label": "EVALUATES", "title": "EVALUATES", "to": "Abrilumab"}, {"arrows": "to", "from": "NCT02698475", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "C-DLQI Score"}, {"arrows": "to", "from": "NCT02698475", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Failed standard treatment"}, {"arrows": "to", "from": "NCT02698475", "label": "INVOLVES", "title": "INVOLVES", "to": "Mild to Severe Plaque Psoriasis"}, {"arrows": "to", "from": "NCT02698475", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "PGA score clear/almost clear"}, {"arrows": "to", "from": "NCT02698475", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PASI100 response"}, {"arrows": "to", "from": "NCT01351675", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Time-to-first event"}, {"arrows": "to", "from": "NCT01351675", "label": "EVALUATES", "title": "EVALUATES", "to": "Bardoxolone Methyl"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Mean change in Systolic BP"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "12 years or older"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Diastolic blood pressure \u003c 60 mm Hg"}, {"arrows": "to", "from": "NCT01351675", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Time to First Relapse Event"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Treatment with an ACE inhibitor and/or an ARB"}, {"arrows": "to", "from": "NCT01351675", "label": "INVOLVES", "title": "INVOLVES", "to": "Overweight and Obese Subjects With Type 2 Diabetes"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Stable Dose Period"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "eGFR \u003e 60 ml/min/1.73 m2"}]);
nodeColors = {};
allNodes = nodes.get({ returnType: "Object" });
for (nodeId in allNodes) {
nodeColors[nodeId] = allNodes[nodeId].color;
}
allEdges = edges.get({ returnType: "Object" });
// adding nodes and edges to the graph
data = {nodes: nodes, edges: edges};
var options = {"nodes": {"font": {"size": 20, "face": "arial"}}, "edges": {"arrows": {"to": {"enabled": true}}, "color": {"inherit": true}, "smooth": {"enabled": true}}, "physics": {"enabled": true, "stabilization": {"iterations": 150}}};
network = new vis.Network(container, data, options);
network.on("stabilizationProgress", function(params) {
document.getElementById('loadingBar').removeAttribute("style");
var maxWidth = 496;
var minWidth = 20;
var widthFactor = params.iterations/params.total;
var width = Math.max(minWidth,maxWidth * widthFactor);
document.getElementById('bar').style.width = width + 'px';
document.getElementById('text').innerHTML = Math.round(widthFactor*100) + '%';
});
network.once("stabilizationIterationsDone", function() {
document.getElementById('text').innerHTML = '100%';
document.getElementById('bar').style.width = '496px';
document.getElementById('loadingBar').style.opacity = 0;
// really clean the dom element
setTimeout(function () {document.getElementById('loadingBar').style.display = 'none';}, 500);
});
return network;
}
drawGraph();
</script>
</body>
</html>